Anti-TSPAN8-anti-CD3 bispecific antibody and anti-TSPAN8 antibody
Patent Information
- Application Number
- JP2022036009
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-16
- Filing Date
- 2022-03-09
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2041-11-15
AI Technical Summary
Current treatments for peritoneal dissemination of gastric cancer and other cancers, such as surgery and chemotherapy, are ineffective, and there is a lack of effective therapies for metastatic gastric cancer and other cancers that have spread to the peritoneum, with no established treatments for ovarian, colorectal, or pancreatic cancer peritoneal dissemination.
Development of an anti-TSPAN8-anti-CD3 bispecific antibody that selectively targets TSPAN8, a protein highly expressed in cancer cells, and CD3 on T cells, bringing cancer cells closer to T cells to enhance cytotoxic activity, and an anti-TSPAN8 antibody that binds to TSPAN8 on cancer cells for killing.
The bispecific antibody enhances cancer cell-killing action by T cells and directly kills cancer cells, prolonging survival in mice and demonstrating antitumor effects, while the anti-TSPAN8 antibody shows cytotoxic activity against cancer cells, indicating potential therapeutic efficacy.
Smart Images

Figure 00000072_0000 
Figure 00000072_0001 
Figure 00000072_0002
Abstract
Description
[Technical Field]
[0001] This invention relates to an anti-TSPAN8-anti-CD3 bispecific antibody and an anti-TSPAN8 antibody that are useful as active ingredients in pharmaceutical compositions used for the treatment of humans. [Background technology]
[0002] Metastatic gastric cancer refers to a condition in which primary gastric cancer invades deeper than the muscular layer, breaks through the serosal membrane surrounding the stomach wall, and metastasizes to various organs via the lymph nodes, abdominal cavity, and even the blood and lymphatic system. More than half of patients with metastatic gastric cancer have metastatic dissemination into the abdominal cavity. In terminally ill patients, symptoms such as abdominal swelling, persistent bloating, pain, nausea, shortness of breath, insomnia, and fatigue are known to occur due to ascites caused by peritoneal dissemination (World J. Gastroenterol., 2016, Vol.22, pp.6829-6840, Int. J. Cancer, 2010, Vol.127, pp.2209-2221). However, complete cure through surgery is difficult for patients with gastric cancer peritoneal metastasis, and chemotherapy, the standard treatment for gastric cancer peritoneal metastasis, is not sufficiently effective. As a result, the five-year survival rate for these patients is very poor, at approximately 2%, and an effective treatment for gastric cancer peritoneal metastasis is desired. Furthermore, peritoneal metastasis is also observed in patients with many other cancers originating from ovarian cancer, colorectal cancer, pancreatic cancer, etc. (Int.J.Adv.Res., 2016, Vol.4, p.735-748), and there is no established treatment for these patients either.
[0003] In the development of antibodies for cancer treatment, various methods have been used to identify tumor-associated antigens (TAAs) that are selectively expressed on cancer cells. One such method involves immunizing animals with cancer cells to produce antibodies and then obtaining antibodies that bind to TAAs expressed on cancer cells (Biochem.Biophys.Res.Commun., 2018, Vol.505, p.181e-186; FEBS Open Bio, 2017, Vol.7, p.627-635).
[0004] Tetraspanin-8 (TSPAN8) is a four-transmembrane protein belonging to the tetraspanin family. It has two extracellular loop regions, a small extracellular loop (SEL) and a large extracellular loop (LEL), and three cytoplasmic domains, forming a molecular cluster with a wide variety of transmembrane and cytoplasmic proteins as a scaffold protein. TSPAN8 is known to be involved in cell adhesion, cell motility, cell activation, and proliferation, and high expression has been observed in gastric cancer, pancreatic cancer, colorectal cancer, liver cancer, etc. A correlation between uptension of TSPAN8 expression and cancer progression or metastasis has been reported (Non-Patent Document 1). Research is being conducted to diagnose and treat cancer using anti-TSPAN8 antibodies (Patent Documents 1-2 and Non-Patent Documents 1-2).
[0005] Cluster of Differentiation 3 (CD3) is a protein that transmits activation signals to T cells by forming a complex with the T cell receptor (TCR) on the surface of T cells. CD3 is a complex composed of five subunits: gamma (γ), delta (δ), epsilon (ε), zeta (ζ), and eta (η) chains, and each subunit forms three types of dimers: εγ, εδ, and ζζ. CD3 is expressed in both normal and neoplastic T cells and is therefore used as a T cell marker. Furthermore, various applications of dual-character antibodies containing various anti-TAA antibodies and anti-CD3 antibodies as pharmaceuticals for cancer treatment have been reported (Non-Patent Literature 3).
[0006] As a groundbreaking method for obtaining cancer cell-selective cytotoxic activity at low antibody concentrations, bispecific T-cell-recruiting antibodies, consisting of various antibody formats, have been reported, and their effects on T-cell-mediated immunotherapy are currently being investigated (Non-Patent Literature 4). Bispecific T-cell-recruiting antibodies are bispecific antibodies that contain an antibody against TAA expressed on the surface of cancer cells and an antibody that binds to T cells. Anti-CD3 antibodies are often used as the antibody that binds to T cells. Bispecific T-cell-recruiting antibodies containing anti-TAA and anti-CD3 antibodies reduce the physical distance between target cancer cells and cytotoxic T lymphocytes (CTLs), activate CTLs with the anti-CD3 antibody, and kill cancer cells through the cytotoxic activity of the CTLs (Redirected T Cell Cytotoxicity; RTCC). Catumaxomab, a bispecific antibody against CD3-anti-epithelial cell adhesion molecule (EpCAM), and blinatumomab, a bispecific antibody against CD3-anti-CD19 (Cluster of Differentiation 19), have already demonstrated clinical efficacy (Int. J. Cancer, 2010, Vol. 127, pp. 2209-2221; N. Engl. J. Med., 2017, Vol. 376, pp. 836-847). Research and development of bispecific T cell recruitment antibodies against various TAAs is currently underway. However, to date, no anti-TSPAN8-anti-CD3 bispecific antibodies are known. [Prior art documents] [Patent Documents]
[0007] [Patent Document 1] International Publication No. 2012 / 010696 [Patent Document 2] International Publication No. 2015 / 130115 [Non-patent literature]
[0008] [Non-Patent Document 1] Biomolecules (Switzerland), 2020; 10(3): p. 383 [Non-Patent Document 2] Cancers (Switzerland), 2019; 11(2): p. 179 [Non-Patent Document 3] Pharmacology and Therapeutics (UK), 2018; 182: p. 161 - 175 [Non-Patent Document 4] mAbs, 2017: 9(2): p. 182 - 212 [Summary of the Invention] [Problems to be Solved by the Invention]
[0009] The problem of the present invention is to provide an anti-TSPAN8 - anti-CD3 bispecific antibody and an anti-TSPAN8 antibody that can be used for the treatment of humans. [Means for Solving the Problems]
[0010] The inventors obtained 16B11 and 16B12, which are anti-TSPAN8 antibodies, by a method of immunizing cancer peritoneal dissemination cells isolated from patients to a human monoclonal antibody-producing mouse to obtain antibodies for the purpose of creating a therapeutic agent selective for cancer cells (Example 1). These antibodies strongly bound to TSPAN8 expressed in cancer peritoneal dissemination cells compared to TSPAN8 expressed in normal cells (Examples 1 to 5). Epitope analysis of 16B11 and 16B12 revealed that these antibodies recognize, as an epitope, a region consisting of the amino acid sequence from amino acid number 126 to 155 of human TSPAN8, and furthermore, it was found that threonine at position 131 of human TSPAN8 is essential for binding to these antibodies (Example 4). In addition, 16B11.1, which is a fully human antibody with the Fc region of 16B11 replaced with a human sequence, was prepared (Example 3), and it was found that this fully human antibody exhibits cytotoxic activity against 60As6-Luc / GFP cells (Example 6). Furthermore, in order to enhance antigen-selective anti-tumor activity by T cells, an anti-TSPAN8-anti-CD3 bispecific antibody containing an anti-CD3-scFv region containing the heavy chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid number 1 to 121 of SEQ ID NO: 6, the light chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid number 1 to 107 of SEQ ID NO: 8, the heavy chain variable region of an anti-CD3 antibody consisting of the amino acid sequence from amino acid number 1 to 125 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody consisting of the amino acid sequence from amino acid number 146 to 254 of SEQ ID NO: 14 was prepared (Example 7). This bispecific antibody binds to TSPAN8 and CD3 (Example 8), exhibits cytotoxic activity against cancer cells expressing TSPAN8 on the cell surface (Examples 9, 10, 12-1, 12-2), and it was confirmed that it extends the survival period of mice and exhibits an anti-tumor effect in vivo (Examples 11 and 12-3).
[0011] That is, the present invention relates to the following [1] to
[55] . [1] A bispecific antibody that binds to TSPAN8 and CD3, (a) The Fab region of the anti-TSPAN8 antibody, comprising a heavy chain fragment containing the heavy chain variable region of the anti-TSPAN8 antibody and a light chain containing the light chain variable region of the anti-TSPAN8 antibody. (b) The anti-CD3-scFv region including the heavy chain variable region and the light chain variable region of the anti-CD3 antibody, and (c) An Fc region consisting of a first Fc polypeptide linked to the heavy chain fragment of the Fab region of (a) and a second Fc polypeptide linked to the anti-CD3-scFv region of (b), A bispecific antibody containing [specific antibody]. [2] [1] A bispecific antibody as described above, The heavy chain variable region of the anti-TSPAN8 antibody includes CDR1 consisting of amino acid sequences from amino acid numbers 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences from amino acid numbers 99 to 110 of SEQ ID NO: 6; and the light chain variable region of the anti-TSPAN8 antibody includes CDR1 consisting of amino acid sequences from amino acid numbers 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences from amino acid numbers 89 to 96 of SEQ ID NO: 8; or, The heavy chain variable region of the anti-TSPAN8 antibody includes CDR1 consisting of amino acid sequences from amino acid numbers 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences from amino acid numbers 99 to 110 of SEQ ID NO: 10. The light chain variable region of the anti-TSPAN8 antibody includes CDR1 consisting of amino acid sequences from amino acid numbers 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences from amino acid numbers 89 to 96 of SEQ ID NO: 12. Bispecific antibodies. [3] [1] A bispecific antibody as described above, The heavy chain variable region of the anti-TSPAN8 antibody consists of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 6, and the light chain variable region of the anti-TSPAN8 antibody consists of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO: 8; or, The heavy chain variable region of the anti-TSPAN8 antibody consists of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 10, and the light chain variable region of the anti-TSPAN8 antibody consists of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO: 12. Bispecific antibodies. [4] [1] A bispecific antibody as described above, The Fab region of the anti-TSPAN8 antibody consists of a heavy chain fragment comprising the amino acid sequence from amino acid numbers 1 to 219 of SEQ ID NO: 6 and a light chain comprising the amino acid sequence of SEQ ID NO: 8; or, The Fab region of the anti-TSPAN8 antibody consists of a heavy chain fragment comprising the amino acid sequence from amino acid numbers 1 to 219 of SEQ ID NO: 10 and a light chain comprising the amino acid sequence of SEQ ID NO: 12. Bispecific antibodies. [5] A bispecific antibody according to any one of [1] to [4], wherein the heavy chain variable region of the anti-CD3 antibody comprises CDR1 consisting of the amino acid sequence from amino acid numbers 31 to 35 of SEQ ID NO: 14, CDR2 consisting of the amino acid sequence from amino acid numbers 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of the amino acid sequence from amino acid numbers 101 to 114 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody comprises CDR1 consisting of the amino acid sequence from amino acid numbers 168 to 181 of SEQ ID NO: 14, CDR2 consisting of the amino acid sequence from amino acid numbers 197 to 203 of SEQ ID NO: 14, and CDR3 consisting of the amino acid sequence from amino acid numbers 236 to 244 of SEQ ID NO: 14. [6] A bispecific antibody as described in any one of [1] to [4], wherein the heavy chain variable region of the anti-CD3 antibody consists of the amino acid sequence from amino acid numbers 1 to 125 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody consists of the amino acid sequence from amino acid numbers 146 to 254 of SEQ ID NO: 14. [7] A bispecific antibody as described in any one of [1] to [4], wherein the anti-CD3-scFv region consists of the amino acid sequence from amino acid numbers 1 to 254 of SEQ ID NO: 14. [8] [1] A bispecific antibody as described above, The bispecific antibody comprises a heavy chain fragment of an anti-TSPAN8 antibody linked to a primary Fc polypeptide, with the heavy chain fragment containing a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6; and a light chain of an anti-TSPAN8 antibody containing a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8. Furthermore, the present invention includes a polypeptide comprising a heavy chain variable region of an anti-CD3 antibody comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences 101 to 114 of SEQ ID NO: 14, and an anti-CD3-scFv region comprising a light chain variable region of an anti-CD3 antibody comprising CDR1 consisting of amino acid sequences 168 to 181 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences 197 to 203 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences 236 to 244 of SEQ ID NO: 14, linked to a secondary Fc polypeptide; or, The bispecific antibody is an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody is linked to a primary Fc polypeptide, and the heavy chain fragment of an anti-TSPAN8 antibody is linked to a light chain variable region containing CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10. The light chain of the anti-CD3 antibody, and the heavy chain variable region of the anti-CD3 antibody, which includes CDR1 consisting of amino acid sequences from amino acid numbers 31 to 35 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences from amino acid numbers 101 to 114 of SEQ ID NO: 14, and the anti-CD3-scFv region, which includes the light chain variable region of the anti-CD3 antibody, which includes CDR1 consisting of amino acid sequences from amino acid numbers 168 to 181 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences from amino acid numbers 197 to 203 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences from amino acid numbers 236 to 244 of SEQ ID NO: 14, and a polypeptide in which the second Fc polypeptide is linked. Bispecific antibodies. [9] [1] A bispecific antibody as described above, The bispecific antibody comprises a heavy chain of an anti-TSPAN8 antibody, in which a heavy chain fragment of an anti-TSPAN8 antibody containing a heavy chain variable region consisting of amino acid sequences 1 to 121 of SEQ ID NO: 6 is linked to a primary Fc polypeptide; a light chain of an anti-TSPAN8 antibody containing a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8 is linked to a secondary Fc polypeptide; or, The bispecific antibody comprises a heavy chain of an anti-TSPAN8 antibody, in which a heavy chain fragment of an anti-TSPAN8 antibody containing a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10 is linked to a first Fc polypeptide; a light chain of an anti-TSPAN8 antibody containing a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 12; and a polypeptide in which a second Fc polypeptide is linked to an anti-CD3-scFv region containing an anti-CD3 antibody containing a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and an anti-CD3 antibody light chain variable region consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14. Bispecific antibodies.
[10] A bispecific antibody according to any one of [1] to [9], comprising an Fc region containing LALA mutations (L234A and L235A (where the mutation sites are amino acid positions according to the EU index in the human Igγ1 constant region)).
[11] A bispecific antibody according to any one of [1] to
[10] , comprising an Fc region containing the N297G mutation (where the mutation site is an amino acid position according to the EU index in the human Igγ1 constant region).
[12] A bispecific antibody according to any one of the items [1] to
[11] , comprising an Fc region containing a knobs into holes mutation.
[13] A bispecific antibody according to any one of [1] to
[12] , comprising an Fc region containing the LALA mutation, the N297G mutation, and the Knobs-into-Holes mutation.
[14] The bispecific antibody described in
[12] or
[13] , wherein the Knobs-into-Hole mutations are the T366W mutation in one Fc polypeptide forming the Fc region, and the T366S, L368A and Y407V mutations in the other Fc polypeptide forming the Fc region (where the mutation sites are amino acid positions according to the EU index in the human Igγ1 constant region).
[15] A bispecific antibody according to any one of [1] to
[14] , comprising an Fc region in which the first Fc polypeptide consists of the amino acid sequence from 235 to 451 of SEQ ID NO: 6, and the second Fc polypeptide consists of an Fc region in which the amino acid sequence from 270 to 486 of SEQ ID NO: 14.
[16] A bispecific antibody as described in any one of [1] to
[15] , wherein the heavy chain fragment of an anti-TSPAN8 antibody and the first Fc polypeptide are linked via a hinge region, and the anti-CD3-scFv region and the second Fc polypeptide are linked via a hinge region.
[17] [1] A bispecific antibody as described above, A bispecific antibody comprising: a heavy chain of an anti-TSPAN8 antibody, in which a heavy chain fragment of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 is linked to a first Fc polypeptide; a light chain of an anti-TSPAN8 antibody, consisting of the amino acid sequence of SEQ ID NO: 8; and a polypeptide, in which an anti-CD3-scFv region consisting of the amino acid sequence of SEQ ID NO: 14 is linked to a second Fc polypeptide.
[18] A post-translation modified bispecific antibody as described in any one of [2] to
[17] .
[19] A bispecific antibody according to
[18] , wherein the post-translational modification is pyroglutamylation of the N-terminus of the heavy chain variable region and / or lysine deletion at the C-terminus of the heavy chain.
[20] Polynucleotides selected from the group consisting of (a) to (e) below: (a) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 6 and a primary Fc polypeptide. (b) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8, (c) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10 and a primary Fc polypeptide. (d) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 12, (e) A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region, which includes the heavy chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14, is linked to a second Fc polypeptide.
[21] Polynucleotides selected from the group consisting of (a) to (c) below: (a) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, in which the heavy chain fragment of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 is linked to the first Fc polypeptide, (b) A polynucleotide containing the base sequence that encodes the light chain of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 8, (c) A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region consisting of the amino acid sequence of SEQ ID NO: 14 is linked to a second Fc polypeptide. An expression vector comprising the polynucleotides described in
[22]
[20] or
[21] .
[23] Host cells transformed with the expression vector described in
[22] .
[24] A host cell comprising a polynucleotide containing a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, in which a heavy chain fragment of an anti-TSPAN8 antibody, including the heavy chain variable region consisting of amino acid sequences 1 to 121 of SEQ ID NO: 6, is linked to a first Fc polypeptide; a polynucleotide containing a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, including the light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8; and a polynucleotide containing a nucleotide sequence encoding a polypeptide, in which a second Fc polypeptide is linked to an anti-CD3-scFv region, including the heavy chain variable region of an anti-CD3 antibody, including the heavy chain variable region consisting of amino acid sequences 1 to 125 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody, including amino acid sequences 146 to 254 of SEQ ID NO: 14.
[25] A host cell comprising a polynucleotide containing a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, in which the heavy chain fragment of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 is linked to a first Fc polypeptide; a polynucleotide containing a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, in which the amino acid sequence of SEQ ID NO: 8 is linked to a second Fc polypeptide; and a polynucleotide containing a nucleotide sequence encoding an anti-CD3-scFv region, in which the amino acid sequence of SEQ ID NO: 14 is linked to a second Fc polypeptide.
[26] A method for producing a bispecific antibody that binds to TSPAN8 and CD3, comprising the step of culturing a host cell as described in any one of
[23] to
[25] .
[27] A pharmaceutical composition comprising a bispecific antibody described in any one of items [1] to
[19] and a pharmaceutically acceptable excipient.
[28] A bispecific antibody as described in any one of [1] to
[19] , for use in the treatment of cancer.
[29] The pharmaceutical composition according to
[27] for the treatment of cancer.
[30] A method for treating cancer, comprising the step of administering a therapeutically effective dose of a bispecific antibody described in any one of the items [1] to
[19] .
[31] Use of a bispecific antibody as described in any one of [1] to
[19] in the manufacture of a pharmaceutical composition for the treatment of cancer.
[32] An anti-TSPAN8 antibody or its antigen-binding fragment that selectively binds to human TSPAN8-expressing cancer cells.
[33] An anti-TSPAN8 antibody or its antigen-binding fragment that binds to at least one amino acid in the human TSPAN8 region from amino acid numbers 126 to 155 of SEQ ID NO: 2.
[34] An anti-TSPAN8 antibody or antigen-binding fragment thereof as described in
[33] , wherein the anti-TSPAN8 antibody or antigen-binding fragment thereof binds to at least the amino acid at amino acid number 131 of SEQ ID NO: 2 present in the human TSPAN8 region.
[35] An anti-TSPAN8 antibody or its antigen-binding fragment selected from (a) and (b) below: (a) An anti-TSPAN8 antibody or its antigen-binding fragment comprising a heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 4, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 4, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 4, and a light chain variable region including CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (b) An anti-TSPAN8 antibody or its antigen-binding fragment comprising a heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10, and a light chain variable region including CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12.
[36] An anti-TSPAN8 antibody or antigen-binding fragment thereof, selected from (a) and (b) below, as described in
[35] : (a) An anti-TSPAN8 antibody or its antigen-binding fragment comprising a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 4, and a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 8; (b) An anti-TSPAN8 antibody or its antigen-binding fragment comprising a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10, and a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 12.
[37] An anti-TSPAN8 antibody as described in
[35] , selected from (a) and (b) below: (a) An anti-TSPAN8 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 4 and a light chain consisting of the amino acid sequence of SEQ ID NO: 8; (b) An anti-TSPAN8 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 10 and a light chain consisting of the amino acid sequence of SEQ ID NO: 12.
[38] An anti-TSPAN8 antibody or antigen-binding fragment thereof that competes with any one of the anti-TSPAN8 antibodies or antigen-binding fragments described in any one of
[33] to
[37] with respect to binding to human TSPAN8-expressing cancer cells.
[39] An anti-TSPAN8 antibody or antigen-binding fragment according to any one of
[32] to
[38] , which is linked to an antibody or antigen-binding fragment against a surface antigen of a T cell or an NK cell.
[40] The anti-TSPAN8 antibody or antigen-binding fragment thereof, wherein the surface antigen of the T cell is CD3, as described in
[39] .
[41] The anti-TSPAN8 antibody or its antigen-binding fragment according to
[40] , wherein the antigen-binding fragment for the surface antigen of T cells is an scFv of an anti-CD3 antibody.
[42] Post-translation modified anti-TSPAN8 antibody or antigen-binding fragment thereof as described in any one of
[32] to
[41] .
[43] The anti-TSPAN8 antibody or antigen-binding fragment thereof as described in
[42] , wherein the post-translational modification is pyroglutamylation of the N-terminus of the heavy chain variable region and / or lysine deletion at the C-terminus of the heavy chain. A fusion or complex of an anti-TSPAN8 antibody or its antigen-binding fragment as described in any one of items
[44] ,
[32] , or
[43] , or cells expressing anti-TSPAN8 or its antigen-binding fragment as described in any one of items
[32] ,
[43] , on their cell surface.
[45] Polynucleotides selected from the group consisting of (a) to (d) below: (a) A polynucleotide containing a base sequence encoding the heavy chain variable region of the anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid number 1 to 121 of SEQ ID NO: 4, (b) A polynucleotide containing a nucleotide sequence encoding the light chain variable region of the anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid number 1 to 107 of SEQ ID NO: 8, (c) A polynucleotide containing a base sequence encoding the heavy chain variable region of the anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid number 1 to 121 of SEQ ID NO: 10. (d) A polynucleotide containing a base sequence that encodes the light chain variable region of the anti-TSPAN8 antibody, consisting of amino acid sequences from amino acid number 1 to 107 of SEQ ID NO. 12.
[46] Polynucleotides selected from the group consisting of (a) to (d) below: (a) A polynucleotide containing the base sequence encoding the heavy chain of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 4, (b) A polynucleotide containing the base sequence that encodes the light chain of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 8, (c) A polynucleotide containing the base sequence encoding the heavy chain of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 10, (d) A polynucleotide containing the base sequence that encodes the light chain of the anti-TSPAN8 antibody, which consists of the amino acid sequence of SEQ ID NO. 12. An expression vector comprising the polynucleotide described in
[47]
[45] or
[46] .
[48] Host cells transformed with the expression vectors described in
[47] .
[49] Host cells selected from (a) or (b) below: (a) Host cells comprising a polynucleotide containing a nucleotide sequence encoding the heavy chain variable region of the anti-TSPAN8 antibody described in
[45] and a polynucleotide containing a nucleotide sequence encoding the light chain variable region of the anti-TSPAN8 antibody described in
[45] ; (b) A host cell comprising a polynucleotide comprising a nucleotide sequence encoding the heavy chain of the anti-TSPAN8 antibody described in
[46] and a polynucleotide comprising a nucleotide sequence encoding the light chain of the anti-TSPAN8 antibody described in
[46] .
[50] A method for producing an anti-TSPAN8 antibody or an antigen-binding fragment thereof, comprising the step of culturing a host cell of either
[48] or
[49] .
[51] An anti-TSPAN8 antibody or antigen-binding fragment thereof as described in any one of
[32] to
[43] , or a fusion, complex or cell as described in
[44] , for use in the treatment of cancer. A pharmaceutical composition comprising an anti-TSPAN8 antibody or its antigen-binding fragment as described in any one of items
[52]
[32] to
[43] , or a fusion, complex or cell as described in
[44] , and further comprising a pharmaceutically acceptable excipient.
[53] The pharmaceutical composition according to
[52] for the treatment of cancer. A method for treating cancer, comprising the steps of administering a therapeutically effective amount of an anti-TSPAN8 antibody or its antigen-binding fragment as described in any one of the items in
[54]
[32] to
[43] , or administering a therapeutically effective amount of a fusion, complex, or cell as described in
[44] .
[55] Use of an anti-TSPAN8 antibody or its antigen-binding fragment as described in any one of
[32] to
[43] , or use of a fusion, complex or cell as described in
[44] , in the manufacture of a pharmaceutical composition for the treatment of cancer. [Effects of the Invention]
[0012] The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention binds to both TSPAN8, a cancer antigen, and CD3, a T cell surface molecule, thereby reducing the physical distance between cancer cells and T cells and enhancing the cancer cell-killing action of T cells. Furthermore, the anti-TSPAN8 antibody of the present invention has the effect of killing cancer cells by binding to TSPAN8. The anti-TSPAN8-anti-CD3 bispecific antibody and the anti-TSPAN8 antibody of the present invention, or a pharmaceutical composition containing such antibodies, can be used for the treatment of cancer. [Brief explanation of the drawing]
[0013] [Figure 1-1] Figure 1-1 shows the results of flow cytometry measurement of the binding affinity of anti-TSPAN8 antibodies (16B11, 16B12, 9F6, 18C10) to KM-291-As. 16B11, 16B12, 9F6, and 18C10 in the figure represent the antibody names. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. White areas in the figure indicate binding of the negative control antibody, while dark gray areas indicate binding of the anti-TSPAN8 antibody. [Figure 1-2] Figure 1-2 shows the results of flow cytometry measurement of the binding affinity of anti-TSPAN8 antibodies (16B11, 9F6, 18C10) to KM-555-As. 16B11, 9F6, and 18C10 in the figure represent the antibody names. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. White areas in the figure indicate binding of the negative control antibody, while dark gray areas indicate binding of the anti-TSPAN8 antibody. [Figure 1-3] Figures 1-3 show the results of flow cytometry measurements of the binding affinity of anti-TSPAN8 antibodies (16B11, 9F6, 18C10) to KM-556-As. 16B11, 9F6, and 18C10 in the figures represent the antibody names. The horizontal axis of the figures represents fluorescence intensity, and the vertical axis represents cell count. White areas in the figures indicate binding of the negative control antibody, while dark gray areas indicate binding of the anti-TSPAN8 antibody. [Figure 2-1]Figure 2-1 shows the results of flow cytometry measurements of the binding affinity of anti-TSPAN8 antibodies (16B11, 16B12, 9F6, 5B7, 12C12, 13A9, 15D1, TAL69) to cultured human peritoneal mesothelial cells. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. White areas in the figure represent binding of the negative control antibody, and dark gray areas represent binding of the anti-TSPAN8 antibody. [Figure 2-2] Figure 2-2 shows the results of flow cytometry measurements of the binding affinity of anti-TSPAN8 antibodies (18C10, 19E4, 21F7, TAL69) to cultured human peritoneal mesothelial cells. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. White areas in the figure indicate binding of the negative control antibody, while dark gray areas indicate binding of the anti-TSPAN8 antibody. [Figure 3-1] Figure 3-1 shows the results of flow cytometry measurement of the binding affinity of anti-TSPAN8 antibodies (16B11, 16B12, 9F6, 18C10, TAL69) to KM-501-As. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. White areas in the figure represent binding of the negative control antibody, and dark gray areas represent binding of the anti-TSPAN8 antibody. [Figure 3-2] Figure 3-2 shows the results of flow cytometry measurement of the binding affinity of anti-TSPAN8 antibodies (16B11, 16B12, 9F6, 18C10, TAL69) to KM-503-As. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. In the figure, white areas indicate binding of the negative control antibody, and dark gray areas indicate binding of the anti-TSPAN8 antibody. [Figure 4] Figure 4 shows the results of flow cytometry measurement of the binding of anti-TSPAN8 antibodies (16B11, 16B12, 9F6, 5B7, 12C12, 13A9, 15D1, 18C10, 19E4, 21F7, TAL69) to human umbilical cord endothelial cells from donor 2. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. White areas in the figure represent binding of the negative control antibody, and dark gray areas represent binding of the anti-TSPAN8 antibody. [Figure 5-1]Figure 5-1 shows the results of flow cytometry measurement of the binding affinity of anti-TSPAN8 antibodies (16B11, 16B12, TAL69) to CHO-K1 cells expressing human mouse TSPAN8-GFP chimeric protein or human rat TSPAN8-GFP chimeric protein (chimeric protein-expressing CHO-K1 cells). The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. In the figure, gray indicates wild-type human TSPAN8-expressing CHO-K1 cells, black indicates chimeric protein-expressing CHO-K1 cells, and white indicates binding of anti-TSPAN8 antibodies to mock cells. Experiments were performed using duplicate cells. [Figure 5-2] Figure 5-2 shows the sequence homology of amino acid numbers 126-155 of four types of TSPAN8 proteins from humans, mice, rats, and cynomolgus monkeys. An asterisk indicates an exact match of amino acids, a dot indicates that three of the four proteins are identical amino acids, and a space indicates that two or more amino acids are different. [Figure 5-3] Figure 5-3 shows the results of flow cytometry measurement of the binding affinity of anti-TSPAN8 antibodies (16B11, 16B12, TAL69) to the human TSPAN8 protein T131A or T131N mutants. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. In the figure, gray indicates binding of the anti-TSPAN8 antibody to wild-type human TSPAN8-expressing CHO-K1 cells, black indicates binding to mutant-expressing CHO-K1 cells, and white indicates binding to mock cells. Experiments were performed using duplicate cells. [Figure 6-1] Figure 6-1 shows the results of flow cytometry measurements of the competitive action of other anti-TSPAN8 antibodies (Competitors (CPTRs): 16B11, 9F6, 18C10, TAL69) against the binding of 16B11 to NSC-15CF. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. In the figure, gray indicates the binding of fluorescently labeled 16B11 in the presence of a negative control antibody, black indicates the binding of fluorescently labeled 16B11 in the presence of each CPTR, and white indicates a histogram of unstained fluorescently labeled 16B11. [Figure 6-2]Figure 6-2 shows the results of flow cytometry measurements of the competitive effect of 16B12 on the binding of fluorescently labeled anti-TSPAN8 antibodies (16B11, 9F6, 18C10) to NSC-15CF. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. In the figure, gray indicates the binding of fluorescently labeled anti-TSPAN8 antibodies in the presence of a negative control antibody, black indicates the binding of fluorescently labeled anti-TSPAN8 antibodies in the presence of 16B12, and white indicates a histogram of unstained cells with fluorescently labeled antibodies. [Figure 6-3] Figure 6-3 shows the results of flow cytometry measurements of the competitive effects of other anti-TSPAN8 antibodies (CPTR: 16B12, 16B11, 9F6, 18C10, TAL69) on the binding of 16B12 to NSC-15CF. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. In the figure, gray indicates the binding of fluorescently labeled 16B12 in the presence of a negative control antibody, black indicates the binding of fluorescently labeled 16B12 in the presence of other anti-TSPAN8 antibodies (CPTR), and white indicates a histogram of cells unstained by the fluorescently labeled antibody. [Figure 7] Figure 7 shows the cytotoxic activity of 16B11.1 in a co-culture system of 60As6-Luc / GFP cells and human NK cells. The horizontal axis represents antibody concentration, and the vertical axis represents cytotoxic activity calculated from luciferase activity produced by 60As6-Luc / GFP cells. ● and ▲ indicate the mean values of cytotoxic activity at various concentrations of the control antibody and 16B11.1, respectively. Error bars indicate the standard deviation. [Figure 8] Figure 8 shows the binding activity of the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody to the TSPAN8 LEL region peptide and CD3εδ complex protein. The horizontal axis represents antibody concentration, and the vertical axis represents the amount of antibody bound. Figures 8-1 and 8-2 show the average binding amounts of the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody to the TSPAN8 LEL region peptide and CD3εδ complex protein, respectively. Error bars indicate the standard deviation. [Figure 9]Figure 9 shows the cytotoxic activity of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody in a co-culture system of 60As6-Luc / GFP cells and human peripheral blood mononuclear cells. The horizontal axis represents antibody concentration, and the vertical axis represents cell proliferation (%) based on the fluorescence area of 60As6-Luc / GFP cells 3 days after antibody addition, with the unadded cell range set to 100%. ● indicates the average cell proliferation at each concentration of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody. Error bars indicate the standard deviation. [Figure 10-1] Figure 10-1 shows the cytotoxic activity of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody against gastric cancer cells in ascites fluid from human gastric cancer patients. The horizontal axis represents the antibody concentration, and the vertical axis represents the number of viable cells (%) three days after antibody addition, with the number of viable cells (without antibody addition) set to 100%. ● and ■ represent the average value of the number of viable cells (%) at the respective concentrations of the control antibody and the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody, respectively. Error bars indicate the standard deviation. [Figure 10-2] Figure 10-2 shows the activation of CD4-positive T cells in ascites fluid cells from human gastric cancer patients by anti-TSPAN8(16B11)-anti-CD3 bispecific antibody, as indicated by the induction of CD25 expression. The horizontal axis represents the antibody concentration. The vertical axis represents the multiplier change in CD25 expression levels 3 days after antibody addition to ascites fluid CD4-positive T cells. ● and ■ represent the average values of the multiplier change in CD25 expression levels at the respective concentrations of the control antibody and the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody, respectively. Error bars represent the standard deviation. [Figure 10-3] Figure 10-3 shows the activation of CD8-positive T cells in ascites fluid cells from human gastric cancer patients by anti-TSPAN8(16B11)-anti-CD3 bispecific antibody, as measured by the induction of CD25 expression. The horizontal axis represents the antibody concentration. The vertical axis shows the multiplier change in CD25 expression 3 days after antibody addition to ascites fluid CD8-positive T cells. ● and ■ represent the average values of the multiplier change in CD25 expression at the respective concentrations of the control antibody and the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody, respectively. Error bars represent the standard deviation. [Figure 11-1]Figure 11-1 shows the antitumor effect of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody in a gastric cancer peritoneal dissemination model. The vertical axis shows the mean amount of luciferin luminescence induced by luciferase expressed by 60As6-Luc / GFP cells in the peritoneal cavity. Error bars indicate the standard error. The horizontal axis shows the antibody dose. The significance level (P-value) was determined by comparing the luminescence of the control group with that of the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody-administered group using Dunnett's multiple comparison test. ** in the figure indicates groups where the P-value is less than the significance level of 0.01. [Figure 11-2] Figure 11-2 shows the effect of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody on survival days in a gastric cancer peritoneal dissemination model. The vertical axis represents survival rate, and the horizontal axis represents days after cancer cell transplantation. Anti-TSPAN8(16B11)-anti-CD3 bispecific antibody and expanded panT cells were administered 7 and 10 days after 60As6-Luc / GFP transplantation, indicated by the triangles (▲). [Figure 12] Figure 12 shows the results of flow cytometry measurements of the binding affinity of 16B11 to various cancer cell lines. The horizontal axis of the figure represents fluorescence intensity, and the vertical axis represents cell count. In the figure, white areas represent binding to the negative control antibody, and dark gray areas represent binding to 16B11. [Figure 13-1] Figure 13-1 shows the cytotoxic activity of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody against various cancer cell lines in co-culture of human peripheral blood mononuclear cells. The horizontal axis represents the antibody concentration, and the vertical axis represents the number of viable cells (%) for each cancer cell line 3 days after antibody addition, with the number of viable cells without antibody addition set to 100%. Each symbol represents the average value (quadruplicate) of the number of viable cells (%) for each cancer cell line at each concentration of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody. [Figure 13-2]Figure 13-2 shows the activation of CD4-positive T cells in co-cultures of human peripheral blood mononuclear cells and various cancer cell lines by anti-TSPAN8(16B11)-anti-CD3 bispecific antibody, as indicated by the induction of CD25 expression. The horizontal axis represents the antibody concentration. The vertical axis represents the quadruplicate change in CD25 expression levels in CD4-positive T cells 3 days after antibody addition. Each symbol represents the average value (quadruplicate) of the quadruplicate change in CD25 expression levels at various concentrations of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody. [Figure 13-3] Figure 13-3 shows the activation of CD8-positive T cells in co-culture of human peripheral blood mononuclear cells and various cancer cell lines by anti-TSPAN8(16B11)-anti-CD3 bispecific antibody, as indicated by the induction of CD25 expression. The horizontal axis represents the antibody concentration. The vertical axis represents the quadruplicate change in CD25 expression levels in CD8-positive T cells 3 days after antibody addition. Each symbol represents the average value (quadruplicate) of the quadruplicate change in CD25 expression levels at various concentrations of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody. [Figure 14] Figure 14 shows the antitumor effect of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody in a human PBMC-transplanted HT-29 cell subcutaneous tumor model. Figure 14-1 shows the mean tumor volume and error bars (standard error) for the number of days after the start of antibody administration. Figure 14-2 shows the tumor volume of each individual 11 days after the start of administration, with the horizontal line showing the mean and standard error, and the horizontal axis showing the antibody dose. The significance level (P-value) was determined by comparing the tumor volume of the PBS-administered group with that of the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody-administered group using Dunnett's multiple comparison test. ** in the figure indicates groups where the P-value is less than the significance level of 0.01. [Modes for carrying out the invention]
[0014] The present invention will be described in detail below.
[0015] <Definition> Terms used herein shall be used in the sense commonly used by those skilled in the art unless otherwise defined below.
[0016] An antibody (or immunoglobulin) is a glycoprotein consisting of a four-chain structure with a symmetrical Y-shaped structure, comprising two heavy chains with a single sequence and two light chains with a single sequence. There are five classes of antibodies: IgG, IgM, IgA, IgD, and IgE. The basic structure of the antibody molecule is common to all classes, with two heavy chains with a molecular weight of 50,000 to 70,000 and two light chains with a molecular weight of 20,000 to 30,000 linked by disulfide bonds and non-covalent bonds, forming an antibody molecule with a Y-shaped four-chain structure and a molecular weight of 150,000 to 190,000. The heavy chains usually consist of polypeptide chains containing about 440 amino acids, and each class has a characteristic structure, corresponding to IgG, IgM, IgA, IgD, and IgE, which are called Igγ, Igμ, Igα, Igδ, and Igε, respectively. Furthermore, IgG has subclasses IgG1, IgG2, IgG3, and IgG4, and the corresponding heavy chains are called Igγ1, Igγ2, Igγ3, and Igγ4, respectively. The light chain usually consists of a polypeptide chain containing about 220 amino acids, and two types are known: L-type and K-type, called Igλ and Igκ, respectively. These two types of light chains can be paired with any type of heavy chain.
[0017] Antibody molecules have four intrachain disulfide bonds in the heavy chain (five in Igμ and Igε) and two in the light chain, forming one loop every 100-110 amino acid residues. Their three-dimensional structures are similar across loops and are called structural units or domains. The N-terminal domain in both the heavy and light chains is called the variable region, and even antibodies produced from the same class (or subclass) of the same animal species exhibit diverse amino acid sequences, which are known to be involved in antibody-antigen binding specificity. The amino acid sequence of the C-terminal domain downstream of the variable region is nearly constant for each class or subclass and is called the constant region. The heavy chain has a heavy chain variable region (VH) and a heavy chain constant region (CH) extending from the N-terminus to the C-terminus. The CH is further divided into three domains from the N-terminus: the CH1 domain, the CH2 domain, and the CH3 domain. The light chain has a light chain variable region (VL) and a light chain constant region (CL) extending from the N-terminus to the C-terminus.
[0018] The amino acid sequences of the three complementarity-determining regions (CDRs) present in the VH and VL regions change very significantly, contributing to the variability of the variable region. The CDRs are regions consisting of approximately 5 to 10 amino acid residues, located in the order of CDR1, CDR2, and CDR3 at the N-terminus of the heavy chain and light chain, respectively, and form the antigen-binding site. On the other hand, the portion of the variable region other than the CDRs is called the framework region (FR), consisting of FR1 to FR4, and its amino acid sequence changes relatively little.
[0019] When an antibody is treated with the protease papain, three antibody fragments are obtained. The two fragments at the N-terminus are called Fab (antigen-binding) regions. In this specification, "Fab region" refers to the region consisting of the VH and CH1 domains of the heavy chain and the light chain (VL and CL), and the antigen is bound at the antigen-binding site at the tip of the Fab region. In this specification, "heavy chain fragment" refers to the fragment consisting of the VH and CH1 domains of the heavy chain that constitute the Fab region. Furthermore, the C-terminal fragment is called the Fc (Fragment, crystallizable) region. In this specification, "Fc polypeptide" refers to a polypeptide consisting of a heavy chain CH2 domain and a CH3 domain, and "Fc region" refers to a complex consisting of two Fc polypeptides. The heavy chain fragment and the Fc polypeptide are linked at a region called the hinge region. Furthermore, the two heavy chains of an antibody are disulfide-bonded at the hinge region.
[0020] In this specification, the term "antigen" is used in its generally accepted sense, and in particular, to refer to a molecule or part of a molecule to which an antigen-binding protein, such as an antibody or antigen-binding fragment, can specifically bind. Antigens can be molecules such as proteins or nucleic acids. A single antigen may have one or more epitopes that can interact with different antibodies, etc.
[0021] In this specification, "epitope" or "antigen determinant" means a specific structural unit of an antigen that is recognized and bound by an antigen-binding protein, and includes all determinants that can be bound by antigen-binding proteins such as antibodies or T cell receptors. Epitope determinants may include chemically active surface groups of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and may have specific three-dimensional structural characteristics and / or specific charge characteristics. If the antigen is a protein, it may include specific amino acids that directly contact the antibody, etc. Generally, antibodies specific to a particular target antigen preferentially recognize epitopes on the target antigen in a complex mixture of proteins and / or macromolecules. Epitopes often consist of amino acid residues and / or sugar side chains that can contact the surface, and usually consist of a sequence of 6 to 10 amino acids or 5 to 8 monosaccharides. Epitopes may have unique three-dimensional structural characteristics and unique charge characteristics. Epitopes may include amino acid residues directly involved in binding and other amino acid residues that are not directly involved in binding. The epitopes to which antigen-binding proteins bind can be identified using methods well known to those skilled in the art, such as mass spectrometry (e.g., hydrogen / deuterium eXchange mass spectrometry; HDX-MS), alanine scanning mutagenesis, crystallography, and peptide competition.
[0022] In this specification, "competition" or "confrontation" means that when two or more antibodies are added to a reaction solution simultaneously or sequentially, one antibody interferes with the binding of the other antibody to the antigen, thereby reducing the binding ability of the other antibody to the antigen.
[0023] In this specification, "antigen-binding fragment" refers to a molecule containing at least one polypeptide chain having antigen-binding activity derived from an antibody. Representative antigen-binding fragments include single-chain variable region fragments (scFv), Fab fragments, Fab' fragments, and F(ab')2 fragments. scFv is a monovalent antigen-binding fragment composed of VH and VL linked by a linker. Fab fragment is a monovalent antigen-binding fragment composed of a light chain and a fragment containing the VH and CH1 domain of the heavy chain. Fab' fragment is a monovalent antigen-binding fragment composed of a light chain and a fragment containing the VH and CH1 domain of the heavy chain and part of the hinge region, the hinge region containing cysteine residues that constituted the inter-heavy chain disulfide bond. F(ab')2 fragment is a divalent molecule in which the Fab' fragment is linked by a disulfide bond. Monovalent means containing one antigen-binding site, and divalent means containing two antigen-binding sites. In this specification, the term "scFv region" refers to a region containing a monovalent antigen-binding fragment, including VH and VL linked by a linker.
[0024] A one-armed antibody is also a type of antigen-binding fragment, comprising one Fab region and one Fc region, wherein the heavy chain fragment of the Fab region is linked to one of the two Fc polypeptides of the Fc region. In one embodiment, the one-armed antibody comprises one heavy chain (VH, CH1 domain, hinge region, Fc polypeptide (CH2 domain and CH3 domain)), one light chain (VL and CL), and an Fc polypeptide.
[0025] In this specification, “multispecific antibody” means an antibody that can specifically bind to two or more different antigens, and depending on the number of antigens it binds to, it is called, for example, a bispecific antibody or a tripspecific antibody. A multispecific antibody includes a complex of two or more antibodies and / or antigen-binding fragments, each capable of binding to a different antigen, and as used herein, “antibody” includes multispecific antibodies unless otherwise specifically limited by the context.
[0026] In this specification, "bispecific antibody" refers to an antibody that can specifically bind to two different antigens. "Anti-TSPAN8-anti-CD3 bispecific antibody" means a bispecific antibody that has binding activity to TSPAN8 and binding activity to CD3.
[0027] In this specification, "human antibody" refers to an antibody having a human immunoglobulin amino acid sequence. In this specification, "humanized antibody" refers to an antibody in which some, most, or all of the amino acid residues other than the CDR are replaced with amino acid residues derived from a human immunoglobulin molecule. The method of humanization is not particularly limited, but humanized antibodies can be produced by referring to, for example, U.S. Patent No. 5,225,539, U.S. Patent No. 6,180,370, etc.
[0028] The amino acid residue numbers of antibodies used herein can be specified according to the Kabat numbering or EU index (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed, 1991, NIH Publication No. 91-3242) by designating these numbering systems.
[0029] In this specification, the terms “first” or “second” are used for convenience to distinguish between two or more types of parts. The use of such terms is not intended to assign any particular order or meaning unless explicitly stated.
[0030] In this specification, “linked” or “linked” means that multiple components (e.g., Fab regions and Fc polypeptides) are linked directly or via one or more intermediaries (e.g., peptide linkers). In this specification, “peptide linker” means one or more arbitrary amino acid residues that can be introduced by genetic engineering to link variable regions. The length of the peptide linker used in the present invention is not particularly limited and can be appropriately selected by those skilled in the art depending on the purpose.
[0031] In this specification, "identity" refers to the Identity value obtained using the EMBOSS Needle (Nucleic Acids Res., 2015, Vol. 43, pW580-W584) with the default parameters. The parameters are as follows: Gap Open Penalty = 10 Gap Extend Penalty = 0.5 Matrix = EBLOSUM62 End Gap Penalty = false
[0032] In this specification, “subject” means a human or other animal in need of prevention or treatment. In some embodiments, it refers to a human being in need of prevention or treatment.
[0033] <The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention> The present invention provides a bispecific antibody that binds to TSPAN8 and CD3 as described below (also referred to as "anti-TSPAN8-anti-CD3 bispecific antibody"): A bispecific antibody that binds to TSPAN8 and CD3, (a) The Fab region of the anti-TSPAN8 antibody, comprising a heavy chain fragment containing the heavy chain variable region of the anti-TSPAN8 antibody and a light chain containing the light chain variable region of the anti-TSPAN8 antibody. (b) Anti-CD3 scFv region including heavy chain variable region and light chain variable region of anti-CD3 antibody, (c) An Fc region consisting of a first Fc polypeptide linked to the heavy chain fragment of the Fab region of (a) and a second Fc polypeptide linked to the anti-CD3-scFv region of (b), A bispecific antibody containing [specific antibody].
[0034] The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention has a structure comprising one Fab region of the first antibody, an scFv region of the second antibody, and one Fc region. Antibodies with such a structure are also called "bottle-opener antibodies" (International Publication No. 2014 / 110601). In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention is a human antibody or a humanized antibody.
[0035] The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention includes an anti-TSPAN8 antibody Fab region, which comprises a heavy chain fragment containing the heavy chain variable region of the anti-TSPAN8 antibody, and a light chain containing the light chain variable region of the anti-TSPAN8 antibody, as the Fab region.
[0036] In one embodiment, the heavy chain variable region of the anti-TSPAN8 antibody includes CDR1 consisting of the amino acid sequence from amino acid numbers 31 to 35 of SEQ ID NO: 6, CDR2 consisting of the amino acid sequence from amino acid numbers 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of the amino acid sequence from amino acid numbers 99 to 110 of SEQ ID NO: 6, and the light chain variable region of the anti-TSPAN8 antibody includes CDR1 consisting of the amino acid sequence from amino acid numbers 24 to 34 of SEQ ID NO: 8, CDR2 consisting of the amino acid sequence from amino acid numbers 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of the amino acid sequence from amino acid numbers 89 to 96 of SEQ ID NO: 8.
[0037] In one embodiment, the heavy chain variable region of the anti-TSPAN8 antibody includes CDR1 consisting of the amino acid sequence from amino acid numbers 31 to 35 of SEQ ID NO: 10, CDR2 consisting of the amino acid sequence from amino acid numbers 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of the amino acid sequence from amino acid numbers 99 to 110 of SEQ ID NO: 10, and the light chain variable region of the anti-TSPAN8 antibody includes CDR1 consisting of the amino acid sequence from amino acid numbers 24 to 34 of SEQ ID NO: 12, CDR2 consisting of the amino acid sequence from amino acid numbers 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of the amino acid sequence from amino acid numbers 89 to 96 of SEQ ID NO: 12.
[0038] In one embodiment, the heavy chain variable region of the anti-TSPAN8 antibody consists of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 6, and the light chain variable region of the anti-TSPAN8 antibody consists of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO: 8.
[0039] In one embodiment, the heavy chain variable region of the anti-TSPAN8 antibody consists of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 10, and the light chain variable region of the anti-TSPAN8 antibody consists of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO: 12.
[0040] The heavy chain constant region from which the CH1 domain of the heavy chain fragment of the anti-TSPAN8 antibody Fab region originates can be any of the constant regions of Igγ, Igμ, Igα, Igδ, or Igε. For example, Igγ can be selected from Igγ1, Igγ2, Igγ3, or Igγ4. In one embodiment, the heavy chain fragment of the anti-TSPAN8 antibody Fab region includes a CH1 domain derived from the human Igγ1 constant region.
[0041] The CL of the light chain of the anti-TSPAN8 antibody Fab region can be selected from either the Igλ or Igκ constant region. In one embodiment, the anti-TSPAN8 antibody Fab region includes a CL that is the Igκ constant region. In one embodiment, the light chain of the anti-TSPAN8 antibody Fab region includes a CL that is the human Igκ constant region.
[0042] In one embodiment, the anti-TSPAN8 antibody Fab region consists of a heavy chain fragment comprising the amino acid sequence of amino acids 1 to 219 of SEQ ID NO: 6 and a light chain comprising the amino acid sequence of SEQ ID NO: 8. In one embodiment, the anti-TSPAN8 antibody Fab region consists of a heavy chain fragment comprising the amino acid sequence of amino acids 1 to 219 of SEQ ID NO: 10 and a light chain comprising the amino acid sequence of SEQ ID NO: 12.
[0043] The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention includes an anti-CD3-scFv region as the scFv region, which includes the heavy chain variable region and the light chain variable region of an anti-CD3 antibody. In the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention, an anti-CD3-scFv region known in the art or an scFv region of an anti-CD3 antibody prepared based on the sequence information of the heavy chain variable region and the light chain variable region of an anti-CD3 antibody known in the art may be used. Known anti-CD3 antibodies include clones such as OKT3, UTCH1, L2K, and TR66, and their sequences have been used as bispecific antibodies (Pharmacol.Ther., 2018, Vol.182, pp.161-175).
[0044] In one embodiment, the heavy chain variable region of the anti-CD3 antibody includes CDR1 consisting of the amino acid sequence from amino acid numbers 31 to 35 of SEQ ID NO: 14, CDR2 consisting of the amino acid sequence from amino acid numbers 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of the amino acid sequence from amino acid numbers 101 to 114 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody includes CDR1 consisting of the amino acid sequence from amino acid numbers 168 to 181 of SEQ ID NO: 14, CDR2 consisting of the amino acid sequence from amino acid numbers 197 to 203 of SEQ ID NO: 14, and CDR3 consisting of the amino acid sequence from amino acid numbers 236 to 244 of SEQ ID NO: 14.
[0045] In one embodiment, the heavy chain variable region of the anti-CD3 antibody consists of the amino acid sequence from amino acid numbers 1 to 125 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody consists of the amino acid sequence from amino acid numbers 146 to 254 of SEQ ID NO: 14.
[0046] In the anti-CD3-scFv region, the type and length of the peptide linker connecting the heavy chain variable region and the light chain variable region of the anti-CD3 antibody are not particularly limited and can be appropriately selected by those skilled in the art. However, a preferred length is 5 amino acids or more (the upper limit is not particularly limited, but is usually 30 amino acids or less, preferably 20 amino acids or less), and particularly preferably 15 amino acids. As the peptide linker, for example, a glycine-serine linker (GS linker) or a glycine-lysine-proline-glycine-serine linker (GKPGS linker) can be used. Examples of such linkers include the following. Ser Gly-Ser Gly-Gly-Ser Ser-Gly-Gly Gly-Gly-Gly-Ser (Sequence ID 15) Ser-Gly-Gly-Gly (SEQ ID NO: 16) Gly-Gly-Gly-Gly-Ser (Sequence ID 17) Ser-Gly-Gly-Gly-Gly (SEQ ID NO: 18) Gly-Gly-Gly-Gly-Gly-Ser (Sequence ID 19) Ser-Gly-Gly-Gly-Gly-Gly (SEQ ID NO: 20) Gly-Gly-Gly-Gly-Gly-Gly-Ser (Sequence ID 21) Ser-Gly-Gly-Gly-Gly-Gly-Gly (SEQ ID NO: 22) (Gly-Gly-Gly-Gly-Ser)n (Ser-Gly-Gly-Gly-Gly)n Gly-Lys-Pro-Gly-Ser (Sequence ID 23) (Gly-Lys-Pro-Gly-Ser)n The above value of n represents an integer greater than or equal to 1. The length and sequence of the peptide linker can be appropriately selected by those skilled in the art depending on the purpose.
[0047] In one embodiment, the anti-CD3-scFv region consists of the amino acid sequence from amino acid numbers 1 to 254 of SEQ ID NO: 14.
[0048] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain fragment of an anti-TSPAN8 antibody linked to a primary Fc polypeptide, the heavy chain of an anti-TSPAN8 antibody comprising a heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6, and a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8. The material contains a polypeptide in which a secondary Fc polypeptide is linked to an anti-CD3-scFv region, which includes the light chain of an anti-TSPAN8 antibody, and the heavy chain variable region of an anti-CD3 antibody comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences 101 to 114 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody comprising CDR1 consisting of amino acid sequences 168 to 181 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences 197 to 203 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences 236 to 244 of SEQ ID NO: 14.In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention has a heavy chain fragment of an anti-TSPAN8 antibody linked to a first Fc polypeptide, the heavy chain of an anti-TSPAN8 antibody comprising a heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10, and a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12. The molecule contains a heavy chain variable region of an anti-CD3 antibody, including the light chain of an anti-TSPAN8 antibody containing the region, and a polypeptide in which a second Fc polypeptide is linked to the light chain variable region of an anti-CD3 antibody, includingTSPAN8 antibody, including the region, including the light chain variable region of an anti-TSPAN8 antibody, including the light chain variable region of an anti-TSPAN8 antibody, including the light chain variable region of an anti-TSPAN8 antibody, including the light chain variable region of an anti-TSPAN8 antibody, including the light chain variable region of an anti-TSPAN8 antibody, including the light chain variable region of an anti
[0049] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody, including a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 6, is linked to a first Fc polypeptide; a light chain of an anti-TSPAN8 antibody, including a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 8; and a polypeptide in which a second Fc polypeptide is linked to an anti-CD3-scFv region, including an anti-CD3 antibody, including a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and an anti-CD3 antibody, including a light chain variable region consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody, including a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10, is linked to a first Fc polypeptide; a light chain of an anti-TSPAN8 antibody, including a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 12; and a polypeptide in which a second Fc polypeptide is linked to an anti-CD3-scFv region, including an anti-CD3 antibody, including a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and an anti-CD3 antibody, including a light chain variable region consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14.
[0050] In the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention, the heavy chain constant region from which the first Fc polypeptide and the second Fc polypeptide constituting the Fc region originate can be selected from any of the constant regions of Igγ, Igμ, Igα, Igδ, or Igε. For example, Igγ can be selected from Igγ1, Igγ2, Igγ3, or Igγ4. In one embodiment, the first Fc polypeptide and the second Fc polypeptide are Fc polypeptides derived from the human Igγ1 constant region.
[0051] The Fc region of the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention may contain mutations that reduce antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). L234A is a substitution of leucine to alanine at amino acid position 234 in the human Igγ1 constant region, following the EU index. L235A is a substitution of leucine to alanine at amino acid position 235 in the human Igγ1 constant region, following the EU index. Amino acid mutations in the human Igγ1 constant region L234A and L235A are called "LALA mutations". These mutations are known to reduce the antibody-dependent cytotoxicity and complement-dependent cytotoxicity of antibodies (Mol.Immunol., 1992, Vol.29, pp.633-639; J.Immunol., 2000, Vol.164, pp.4178-4184).
[0052] The Fc region in the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention may further include mutations based on other known techniques. For example, the Fc region may include the N297G mutation (Protein cell, 2018, Vol.9, pp.63-73) or a mutation based on the Knobs into Holes technique (hereinafter also referred to as the "Knobs into Holes mutation"). The knobs-into-holes technique is a method that promotes heterodimerization of heavy chains by replacing an amino acid side chain in the CH3 region of one heavy chain with a larger side chain (knob; projection) and replacing an amino acid side chain in the CH3 region of the other heavy chain with a smaller side chain (hole; void), thereby positioning the projection within the void and efficiently obtaining the desired heterodimerized antibody molecule (Nature, 1994, Vol.372, pp.379-383; Nature Biotech., 1998, Vol.16, pp.677-681; J.Mol.Biol., 1997, Vol.270, pp.26-35; Proc.Natl.Acad.Sci.USA, 2013, Vol.110, pp.E2987-E2996).
[0053] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention includes an Fc region containing L234A and L235A amino acid mutations (LALA mutations). In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention includes an Fc region containing an N297G mutation. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention includes an Fc region containing a Knobs-into-Holes mutation. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention includes an Fc region containing one or more mutations from among the L234A and L235A amino acid mutations (LALA mutations), the N297G mutation, and the Knobs-into-Holes mutation. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention includes an Fc region containing L234A and L235A amino acid mutations (LALA mutations), the N297G mutation, and the Knobs-into-Holes mutation. In one embodiment, the Knobs-into-Hole mutations included in the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention are the T366W mutation in one Fc polypeptide forming its Fc region, and the T366S, L368A, and Y407V mutations in the other Fc polypeptide forming its Fc region (see International Publication No. 1998 / 050431).
[0054] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises an Fc region consisting of a first Fc polypeptide comprising the amino acid sequence from amino acid numbers 235 to 451 of SEQ ID NO: 6 and a second Fc polypeptide comprising the amino acid sequence from amino acid numbers 270 to 486 of SEQ ID NO: 14.
[0055] In this specification, descriptions of amino acid mutations such as the LALA mutation, N297G mutation, and Knobs-into-Hole mutation are based on the amino acid positions according to the EU index in the human Igγ1 constant region. For example, as mentioned above, L234A is a substitution of leucine to alanine at amino acid position 234 in the human Igγ1 constant region according to the EU index.
[0056] In the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention, a heavy chain fragment containing the heavy chain variable region of the anti-TSPAN8 antibody and an Fc polypeptide (first Fc polypeptide) may be linked via a hinge region to constitute the heavy chain of the anti-TSPAN8 antibody. Furthermore, in the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention, the anti-CD3-scFv region and the Fc polypeptide (second Fc polypeptide) may be linked via a hinge region.
[0057] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment containing the heavy chain variable region of the anti-TSPAN8 antibody and a first Fc polypeptide linked via a hinge region. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a polypeptide in which an anti-CD3-scFv region and a second Fc polypeptide linked via a hinge region. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment containing the heavy chain variable region of the anti-TSPAN8 antibody and a first Fc polypeptide linked via a hinge region, and a polypeptide in which an anti-CD3-scFv region and a second Fc polypeptide linked via a hinge region.
[0058] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain fragment of an anti-TSPAN8 antibody containing a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6, and a first Fc polypeptide linked to the heavy chain of an anti-TSPAN8 antibody via a hinge region, and a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8. The material contains a heavy chain variable region of an anti-CD3 antibody, which includes the light chain of an anti-TSPAN8 antibody, and a secondary Fc polypeptide linked via a hinge region. This region includes the light chain of an anti-TSPAN8 antibody, and the heavy chain variable region of an anti-CD3 antibody, which includes CDR1 consisting of amino acid sequences from amino acid numbers 31 to 35 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences from amino acid numbers 101 to 114 of SEQ ID NO: 14.In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain fragment of an anti-TSPAN8 antibody containing a heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10, and a first Fc polypeptide linked to the heavy chain of an anti-TSPAN8 antibody via a hinge region, and a light chain variable region including CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12. The material includes a heavy chain variable region of an anti-CD3 antibody containing the region of an anti-TSPAN8 antibody, and a heavy chain variable region of an anti-CD3 antibody containing CDR1 consisting of amino acid sequences from amino acid numbers 31 to 35 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences from amino acid numbers 101 to 114 of SEQ ID NO: 14, and an anti-CD3-scFv region containing the light chain variable region of an anti-CD3 antibody containing CDR1 consisting of amino acid sequences from amino acid numbers 168 to 181 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences from amino acid numbers 197 to 203 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences from amino acid numbers 236 to 244 of SEQ ID NO: 14, in which a secondary Fc polypeptide is linked via a hinge region.
[0059] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody, including a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 6, is linked to a first Fc polypeptide via a hinge region; a light chain of an anti-TSPAN8 antibody, including a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 8; and a polypeptide in which an anti-CD3-scFv region, including an anti-CD3 antibody, including a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and an anti-CD3 antibody, including a light chain variable region consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14, is linked to a second Fc polypeptide via a hinge region. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody, comprising a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10, is linked to a first Fc polypeptide via a hinge region; a light chain of an anti-TSPAN8 antibody, comprising a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 12; and a polypeptide in which an anti-CD3-scFv region, comprising an anti-CD3 antibody, comprising a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and an anti-CD3 antibody, comprising an anti-CD3-scFv region, comprising an anti-CD3 antibody amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14, is linked to a second Fc polypeptide via a hinge region.
[0060] In one embodiment, the heavy chain of the anti-TSPAN8 antibody, in which a heavy chain fragment of the anti-TSPAN8 antibody containing the heavy chain variable region of the anti-TSPAN8 antibody and a first Fc polypeptide are linked via a hinge region, consists of the amino acid sequence of SEQ ID NO: 6 or 10. In one embodiment, the heavy chain of the anti-TSPAN8 antibody, in which a heavy chain fragment of the anti-TSPAN8 antibody containing the heavy chain variable region of the anti-TSPAN8 antibody and a first Fc polypeptide are linked via a hinge region, consists of the amino acid sequence of SEQ ID NO: 6. In one embodiment, the light chain of the anti-TSPAN8 antibody consists of the amino acid sequence of SEQ ID NO: 8 or 12. In one embodiment, the light chain of the anti-TSPAN8 antibody consists of the amino acid sequence of SEQ ID NO: 8. In one embodiment, the polypeptide, in which an anti-CD3-scFv region and a second Fc polypeptide are linked via a hinge region, consists of the amino acid sequence of SEQ ID NO: 14. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention comprises a heavy chain fragment of an anti-TSPAN8 antibody including a heavy chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 or 10, a heavy chain of an anti-TSPAN8 antibody in which the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 8 or 12 and a first Fc polypeptide are linked, and a polypeptide in which the anti-CD3-scFv region consisting of the amino acid sequence of SEQ ID NO: 14 and a second Fc polypeptide are linked.
[0061] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention is a bispecific antibody comprising: a heavy chain of an anti-TSPAN8 antibody having a heavy chain fragment of an anti-TSPAN8 antibody having the amino acid sequence of SEQ ID NO: 6 linked to a first Fc polypeptide; a light chain of an anti-TSPAN8 antibody having the amino acid sequence of SEQ ID NO: 8; and a polypeptide having an anti-CD3-scFv region having the amino acid sequence of SEQ ID NO: 14 linked to a second Fc polypeptide.
[0062] In this specification, "post-translational modification" refers to modifications that occur in antibodies after translation when they are expressed in cells. Examples of post-translational modifications include pyroglutamylation, glycosylation, oxidation, deamidation, and glycation of glutamine or glutamic acid at the N-terminus of the heavy chain, as well as lysine deletion due to cleavage of lysine at the C-terminus of the heavy chain by carboxypeptidase. Such post-translational modifications are known to occur in various antibodies (J. Pharm. Sci., 2008, Vol. 97, pp. 2426-2447).
[0063] In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention may be post-translationally modified. In one embodiment, the post-translationally modified antibody is pyroglutamylation of the N-terminus of the heavy chain variable region and / or lysine deletion of the heavy chain C-terminus. It is known in the art that post-translationally modified antibodies by N-terminus pyroglutamylation or C-terminus lysine deletion do not affect antibody activity (Analytical Biochemistry, 2006, Vol.348, pp.24-39).
[0064] The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention binds to human TSPAN8 (gene number: NM_004616.2) and human CD3εδ complex protein (CD3ε gene number: NM_000733.3, CD3δ gene number: NM_000732.4 or NM_001040651.1). Whether or not the antibody binds to human TSPAN8 and human CD3εδ complex protein can be confirmed using known binding activity measurement methods. Examples of methods for measuring binding activity include enzyme-linked immunosorbent assay (ELISA) and flow cytometry. When using ELISA, for example, the method described in Example 8 can be used, and when using flow cytometry, for example, the method described in Example 1 can be used.
[0065] The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention can be produced by a person skilled in the art using methods known in the art, based on the sequence information of the heavy chain variable region and light chain variable region of the anti-TSPAN8 antibody and the anti-CD3-scFv region disclosed herein. Furthermore, the anti-CD3-scFv region of the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention can be produced by a person skilled in the art using methods known in the art, based on the sequence information of the heavy chain variable region and light chain variable region of a known anti-CD3 antibody. In one embodiment, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention is a humanized antibody or a human antibody. In the production of the humanized antibody, back mutations may be introduced as appropriate using methods well known to a person skilled in the art (Bioinformatics, 2015, Vol. 31, pp. 434-435). The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention is not particularly limited, but can be produced, for example, according to the method described below in <<Method for producing the bispecific antibody of the present invention and the bispecific antibody of the present invention produced by the method>>.
[0066] <Polynucleotides of the bispecific antibody of the present invention> The present invention also provides the following polynucleotides (also referred to as "polynucleotides of the bispecific antibody of the present invention") which can be used to produce the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention. (1) A polynucleotide containing a heavy chain fragment of the anti-TSPAN8 antibody and a base sequence encoding the heavy chain of the anti-TSPAN8 antibody, including the first Fc polypeptide; (2) Polynucleotides containing the base sequence encoding the light chain of the anti-TSPAN8 antibody; (3) A polynucleotide comprising a base sequence encoding a polypeptide comprising an anti-CD3-scFv region and a polypeptide comprising a second Fc polypeptide.
[0067] In one embodiment of the polynucleotide described in (1) above, the polynucleotide of the bispecific antibody of the present invention is a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a primary Fc polypeptide and includes a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6; (b) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which includes a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10, linked to a primary Fc polypeptide.
[0068] In one embodiment of the polynucleotide described in (1) above, the polynucleotide of the bispecific antibody of the present invention is a polynucleotide selected from (a) and (b) below: (a) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody, which includes a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of the sequence number, with a primary Fc polypeptide; (b) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody, which includes a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10, with a primary Fc polypeptide.
[0069] In one embodiment of the polynucleotide described in (1) above, the polynucleotide of the bispecific antibody of the present invention is a polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, in which a heavy chain fragment of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 is linked to a first Fc polypeptide.
[0070] In one embodiment of the polynucleotide described in (2) above, the polynucleotide of the bispecific antibody of the present invention is a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12.
[0071] In one embodiment of the polynucleotide described in (2) above, the polynucleotide of the bispecific antibody of the present invention is a polynucleotide selected from (a) and (b) below: (a) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of the amino acid sequence from amino acid numbers 1 to 107 of the sequence number 8; (b) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 12.
[0072] In one embodiment of the polynucleotide described in (2) above, the polynucleotide of the bispecific antibody of the present invention is a polynucleotide comprising a base sequence that encodes the light chain of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 8.
[0073] In one embodiment of the polynucleotide described in (3) above, the polynucleotide of the bispecific antibody of the present invention is the following polynucleotide: A polynucleotide comprising a base sequence encoding a polypeptide in which a secondary Fc polypeptide is linked to an anti-CD3 antibody, including the heavy chain variable region of an anti-CD3 antibody comprising the amino acid sequence CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 14, the amino acid sequence CDR2 consisting of amino acid sequences 50 to 68 of SEQ ID NO: 14, and the amino acid sequence CDR3 consisting of amino acid sequences 101 to 114 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody comprising the amino acid sequence CDR1 consisting of amino acid sequences 168 to 181 of SEQ ID NO: 14, the amino acid sequence CDR2 consisting of amino acid sequences 197 to 203 of SEQ ID NO: 14, and the amino acid sequence CDR3 consisting of amino acid sequences 236 to 244 of SEQ ID NO: 14.
[0074] In one embodiment of the polynucleotide described in (3) above, the polynucleotide of the bispecific antibody of the present invention is the following polynucleotide: A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region, which includes the heavy chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14, is linked to a second Fc polypeptide.
[0075] In one embodiment of the polynucleotide described in (3) above, the polynucleotide of the bispecific antibody of the present invention is a polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region consisting of the amino acid sequence of SEQ ID NO: 14 is linked to a second Fc polypeptide.
[0076] The polynucleotide of the bispecific antibody of the present invention can be prepared by those skilled in the art using methods known in the art, based on its base sequence. For example, the polynucleotide of the bispecific antibody of the present invention can be synthesized using gene synthesis methods known in the art. Various methods known to those skilled in the art can be used as such gene synthesis methods, such as the antibody gene synthesis method described in International Publication No. 90 / 07861.
[0077] <Expression vector for the bispecific antibody of the present invention> The present invention also provides an expression vector (also referred to as "expression vector of the bispecific antibody of the present invention") containing polynucleotides of the bispecific antibody of the present invention as described in (1) to (3) below. These polynucleotides may each be contained in a separate vector, or multiple polynucleotides may be contained in a single vector. (1) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, in which the heavy chain fragment of the anti-TSPAN8 antibody is linked to the first Fc polypeptide; (2) Polynucleotides containing the base sequence encoding the light chain of the anti-TSPAN8 antibody; (3) A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region and a polypeptide containing a second Fc polypeptide are linked.
[0078] In one embodiment of the expression vector for the bispecific antibody of the present invention, which contains the polynucleotide described in (1) above, the expression vector contains a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a primary Fc polypeptide and includes a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6; (b) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which includes a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10, linked to a primary Fc polypeptide.
[0079] In one embodiment of the expression vector for the bispecific antibody of the present invention, which contains the polynucleotide described in (1) above, the expression vector contains a polynucleotide selected from (a) and (b) below: (a) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody, which includes a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of the sequence number, with a primary Fc polypeptide; (b) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody, which includes a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10, with a primary Fc polypeptide.
[0080] In one embodiment of the bispecific antibody expression vector of the present invention comprising the polynucleotide described in (1) above, the expression vector comprises a polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 is linked to a first Fc polypeptide.
[0081] In one embodiment of the expression vector for the bispecific antibody of the present invention, which contains the polynucleotide described in (2) above, the expression vector contains a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12.
[0082] In one embodiment of the expression vector for the bispecific antibody of the present invention, which contains the polynucleotide described in (2) above, the expression vector contains a polynucleotide selected from (a) and (b) below: (a) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of the amino acid sequence from amino acid numbers 1 to 107 of the sequence number 8; (b) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 12.
[0083] In one embodiment of the expression vector for the bispecific antibody of the present invention, which includes the polynucleotide described in (2) above, the expression vector includes a polynucleotide comprising a base sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 8.
[0084] In one embodiment of the expression vector for the bispecific antibody of the present invention, which contains the polynucleotide described in (3) above, the expression vector comprises the following polynucleotides: A polynucleotide comprising a base sequence encoding a polypeptide in which a secondary Fc polypeptide is linked to an anti-CD3 antibody, including the heavy chain variable region of an anti-CD3 antibody comprising the amino acid sequence CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 14, the amino acid sequence CDR2 consisting of amino acid sequences 50 to 68 of SEQ ID NO: 14, and the amino acid sequence CDR3 consisting of amino acid sequences 101 to 114 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody comprising the amino acid sequence CDR1 consisting of amino acid sequences 168 to 181 of SEQ ID NO: 14, the amino acid sequence CDR2 consisting of amino acid sequences 197 to 203 of SEQ ID NO: 14, and the amino acid sequence CDR3 consisting of amino acid sequences 236 to 244 of SEQ ID NO: 14.
[0085] In one embodiment of the expression vector for the bispecific antibody of the present invention, which contains the polynucleotide described in (3) above, the expression vector comprises the following polynucleotides: A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region, which includes the heavy chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14, is linked to a second Fc polypeptide.
[0086] In one embodiment of the expression vector for the bispecific antibody of the present invention, which includes the polynucleotide described in (3) above, the expression vector includes a polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region consisting of the amino acid sequence of SEQ ID NO: 14 is linked to a second Fc polypeptide.
[0087] In one embodiment, the expression vector for the bispecific antibody of the present invention is an expression vector comprising one or more polynucleotides selected from (a) to (e) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a primary Fc polypeptide and includes a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6; (b) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (c) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, in which a heavy chain fragment of an anti-TSPAN8 antibody is linked to a primary Fc polypeptide, including a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10. (d) A polynucleotide comprising a base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences from amino acid numbers 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences from amino acid numbers 89 to 96 of SEQ ID NO: 12. (e) A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region and a second Fc polypeptide are linked, comprising the heavy chain variable region of an anti-CD3 antibody comprising the amino acid sequence of amino acids 31 to 35 of SEQ ID NO: 14, the amino acid sequence of amino acids 50 to 68 of SEQ ID NO: 14, and the amino acid sequence of amino acids 101 to 114 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody comprising the amino acid sequence of amino acids 168 to 181 of SEQ ID NO: 14, the amino acid sequence of amino acids 197 to 203 of SEQ ID NO: 14, and the amino acid sequence of amino acids 236 to 244 of SEQ ID NO: 14.
[0088] In one embodiment, the expression vector for the bispecific antibody of the present invention is an expression vector comprising one or more polynucleotides selected from (a) to (e) below: (a) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody, which includes a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of the sequence number, with a primary Fc polypeptide; (b) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of the amino acid sequence from amino acid numbers 1 to 107 of the sequence number 8; (c) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody, which includes a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10, with a primary Fc polypeptide. (d) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of amino acid sequences from amino acid number 1 to 107 of SEQ ID NO: 12. (e) A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region, which includes the heavy chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14, is linked to a second Fc polypeptide.
[0089] In one embodiment, the expression vector for the bispecific antibody of the present invention is an expression vector comprising one or more polynucleotides selected from (a) to (c) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking the heavy chain fragment of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 with a primary Fc polypeptide; (b) A polynucleotide containing the base sequence encoding the light chain of the anti-TSPAN8 antibody, which consists of the amino acid sequence of SEQ ID NO: 8; (c) A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region consisting of the amino acid sequence of SEQ ID NO: 14 is linked to a second Fc polypeptide.
[0090] The expression vector for the bispecific antibody of the present invention is not particularly limited, as long as it can produce the polynucleotide of the present invention in various host cells such as eukaryotic cells (e.g., animal cells, insect cells, plant cells, yeast) and / or prokaryotic cells (e.g., Escherichia coli). Examples of such expression vectors include plasmid vectors and viral vectors. Examples of plasmid vectors include the pcDNA series (Thermo Fisher Scientific), pALTER®-MAX (Promega), pHEK293 Ultra Expression Vector (Takara Bio), pEE6.4 or pEE12.4 (Lonza Biologics). Examples of viral vectors include lentiviruses, adenoviruses, retroviruses, and adeno-associated viruses. For example, when using a lentivirus to introduce the polynucleotide of the present invention into cells, the lentivirus could be the pLVSIN-CMV / EF1α vector (Takara Bio), the pLenti vector (Thermo Fisher Scientific), etc. In one embodiment, the vector used for the expression vector of the bispecific antibody of the present invention is pcDNA TM 3.4-TOPO® (registered trademark) (Thermo Fisher Scientific, Inc.) and pcDNA TM 3.1 (Thermo Fisher Scientific).
[0091] The expression vector for the bispecific antibody of the present invention may include a promoter operably linked to the polynucleotide of the bispecific antibody of the present invention. Examples of promoters for expressing the polynucleotide of the bispecific antibody of the present invention in animal cells include virus-derived promoters such as CMV, RSV, and SV40, actin promoters, EF (elongation factor) 1α promoters, and heat shock promoters. Examples of promoters for expressing the polynucleotide of the bispecific antibody of the present invention in bacteria (e.g., Escherichia species) include trp promoters, lac promoters, λPL promoters, and tac promoters. Examples of promoters for expressing the polynucleotide of the bispecific antibody of the present invention in yeast include GAL1 promoters, GAL10 promoters, PH05 promoters, PGK promoters, GAP promoters, and ADH promoters.
[0092] When using animal cells, insect cells, or yeast as host cells, the expression vector of the bispecific antibody of the present invention may include a start codon and a stop codon. In this case, it may also include an enhancer sequence, the 5' and 3' untranslated regions of the gene encoding the antibody of the present invention or its heavy or light chain, a secretion signal sequence, a splicing junction, a polyadenylation site, or a repeatable unit. When using Escherichia coli as host cells, the expression vector of the present invention may include a start codon, a stop codon, a terminator region, and a repeatable unit. The expression vector of the present invention may also include commonly used drug selection marker genes (e.g., tetracycline resistance gene, ampicillin resistance gene, kanamycin resistance gene, neomycin resistance gene, dihydrofolate reductase gene) depending on the purpose.
[0093] <Host cells transformed by the present invention> The present invention also provides host cells transformed with an expression vector for the bispecific antibody of the present invention (also referred to as "transformed host cells of the present invention"). The transformed host cells of the present invention may, upon transformation with the expression vector for the bispecific antibody of the present invention, contain one or more polynucleotides of the following (1) to (3) of the bispecific antibody polynucleotides of the present invention, and in one embodiment, the transformed host cells of the present invention contain all of the following (1) to (3): (1) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, in which the heavy chain fragment of the anti-TSPAN8 antibody is linked to the first Fc polypeptide; (2) Polynucleotides containing the base sequence encoding the light chain of the anti-TSPAN8 antibody; (3) A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region and a polypeptide containing a second Fc polypeptide are linked.
[0094] The host cells to be transformed are not particularly limited, as long as they are compatible with the expression vector used and can be transformed with the expression vector to express an antibody or fusion. Examples of host cells to be transformed include various cells such as conventional cells or artificially established cells commonly used in the art of the present invention (e.g., animal cells (e.g., CHO-K1 cells, ExpiCHO-S® cells, CHOK1SV cells, CHO-DG44 cells, HEK293 cells, NS0 cells), insect cells (e.g., Sf9), bacteria (e.g., Escherichia species), yeasts (e.g., Saccharomyces species, Pichia species), etc.). In one embodiment, the host cells of the present invention are CHO-K1 cells or ExpiCHO-S cells.
[0095] The method for transforming host cells is not particularly limited, but methods commonly used by those skilled in the art, such as the calcium phosphate method, electroporation, or lipofection, can be used.
[0096] The selection of transformed host cells can be carried out by methods commonly used by those skilled in the art. These selection methods may include, for example, drug selection methods using a drug selection marker gene and drugs such as tetracycline, ampicillin, neomycin, or hygromycin, as well as cell isolation methods such as ultradilution, single-cell sorting, or colony pickup.
[0097] In one embodiment of the transformed host cell of the present invention containing the polynucleotide described in (1) above, the host cell contains a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a primary Fc polypeptide and includes a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6; (b) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which includes a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10, linked to a primary Fc polypeptide.
[0098] In one embodiment of the transformed host cell of the present invention containing the polynucleotide described in (1) above, the host cell contains a polynucleotide selected from (a) and (b) below: (a) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody, which includes a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of the sequence number, with a primary Fc polypeptide; (b) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody, which includes a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10, with a primary Fc polypeptide.
[0099] In one embodiment of the transformed host cell of the present invention comprising the polynucleotide of (1) above, the host cell comprises a polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 is linked to a first Fc polypeptide.
[0100] In one embodiment of the transformed host cell of the present invention containing the polynucleotide of (2) above, the host cell contains a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12.
[0101] In one embodiment of the transformed host cell of the present invention containing the polynucleotide of (2) above, the host cell contains a polynucleotide selected from (a) and (b) below: (a) A polynucleotide containing a base sequence that encodes an anti-TSPAN8 antibody light chain, which includes a light chain variable region consisting of the amino acid sequence from amino acid numbers 1 to 107 of the sequence number 8; (b) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 12.
[0102] In one embodiment of the transformed host cell of the present invention containing the polynucleotide of (2) above, the host cell contains a polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 8.
[0103] In one embodiment of a transformed host cell of the present invention containing the polynucleotides described in (3) above, the host cell contains the following polynucleotides: A polynucleotide comprising a base sequence encoding a polypeptide in which a secondary Fc polypeptide is linked to an anti-CD3 antibody, including the heavy chain variable region of an anti-CD3 antibody comprising the amino acid sequence CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 14, the amino acid sequence CDR2 consisting of amino acid sequences 50 to 68 of SEQ ID NO: 14, and the amino acid sequence CDR3 consisting of amino acid sequences 101 to 114 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody comprising the amino acid sequence CDR1 consisting of amino acid sequences 168 to 181 of SEQ ID NO: 14, the amino acid sequence CDR2 consisting of amino acid sequences 197 to 203 of SEQ ID NO: 14, and the amino acid sequence CDR3 consisting of amino acid sequences 236 to 244 of SEQ ID NO: 14.
[0104] In one embodiment of a transformed host cell of the present invention containing the polynucleotides described in (3) above, the host cell contains the following polynucleotides: A polynucleotide containing a base sequence encoding a polypeptide formed by linking an anti-CD3-scFv region, which includes the heavy chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 1 to 125 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody consisting of amino acid sequences from amino acid numbers 146 to 254 of SEQ ID NO: 14, with a secondary Fc polypeptide.
[0105] In one embodiment of the transformed host cell of the present invention containing the polynucleotide of (3) above, the host cell contains a polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv and a second Fc polypeptide are linked, the amino acid sequence of SEQ ID NO: 14.
[0106] In one embodiment, the host cell transformed by the present invention is a host cell containing one or more polynucleotides selected from (a) to (e) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a primary Fc polypeptide and includes a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6; (b) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (c) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking a heavy chain fragment of an anti-TSPAN8 antibody with a primary Fc polypeptide, including a heavy chain variable region comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10; (d) A polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12; (e) A polynucleotide comprising a base sequence encoding a polypeptide in which an anti-CD3-scFv region and a second Fc polypeptide are linked, comprising the heavy chain variable region of an anti-CD3 antibody comprising the amino acid sequence of amino acids 31 to 35 of SEQ ID NO: 14, the amino acid sequence of amino acids 50 to 68 of SEQ ID NO: 14, and the amino acid sequence of amino acids 101 to 114 of SEQ ID NO: 14, and the light chain variable region of an anti-CD3 antibody comprising the amino acid sequence of amino acids 168 to 181 of SEQ ID NO: 14, the amino acid sequence of amino acids 197 to 203 of SEQ ID NO: 14, and the amino acid sequence of amino acids 236 to 244 of SEQ ID NO: 14.
[0107] In one embodiment, the host cell transformed by the present invention is a host cell containing one or more polynucleotides selected from (a) to (e) below: (a) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 6 and a primary Fc polypeptide. (b) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8, (c) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is linked to a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 10 and a primary Fc polypeptide. (d) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody, which includes a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 12, (e) A polynucleotide comprising a base sequence encoding a polypeptide in which anti-CD3-scFv and a second Fc polypeptide are linked, including the heavy chain variable region of an anti-CD3 antibody consisting of the amino acid sequence from amino acid numbers 1 to 125 of SEQ ID NO: 14 and the light chain variable region of an anti-CD3 antibody consisting of the amino acid sequence from amino acid numbers 146 to 254 of SEQ ID NO: 14.
[0108] In one embodiment, the host cell transformed by the present invention is a host cell containing a polynucleotide selected from (a) to (c) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody, which is formed by linking the heavy chain fragment of the anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6 with a primary Fc polypeptide; (b) A polynucleotide containing the base sequence encoding the light chain of the anti-TSPAN8 antibody, which consists of the amino acid sequence of SEQ ID NO: 8; (c) A polynucleotide containing a base sequence encoding a polypeptide in which an anti-CD3-scFv and a secondary Fc polypeptide, consisting of the amino acid sequence of SEQ ID NO: 14, are linked.
[0109] In one embodiment, the transformed host cell of the present invention contains a polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 6, a polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence of SEQ ID NO: 8, and a polynucleotide comprising a nucleotide sequence encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO: 14.
[0110] <Method for producing the bispecific antibody of the present invention> The present invention also provides a method for producing the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention (also referred to as the "production method of the present invention"). The production method of the present invention may include, but is not limited to, the steps of culturing the transformed host cells described in <Transformed Host Cells of the Present Invention> and expressing the antibody in the cells or the culture supernatant, and recovering, isolating, and purifying the antibody.
[0111] The culture of the transformed host cells of the present invention can be carried out by known methods. Culture conditions, such as temperature, pH of the culture medium, and culture time, can be appropriately selected by those skilled in the art. When the host cells are animal cells, for example, MEM medium containing about 5-20% fetal bovine serum (Science, 1959, Vol. 130, pp. 432-437), DMEM medium (Virol., 1959, Vol. 8, pp. 396), RPMI-1640 medium (J. Am. Med. Assoc., 1967, Vol. 199, pp. 519), 199 medium (Exp. Biol. Med., 1950, Vol. 73, pp. 1-8) can be used as the culture medium. The pH of the culture medium is, for example, about 6-8, and the culture is usually carried out at about 30-40°C for about 15-336 hours, with aeration and stirring as necessary. When the host cells are insect cells, a culture medium such as Grace's medium containing fetal bovine serum (Proc. Natl. Acad. Sci. USA., 1985, Vol. 82, p. 8404) can be used. The pH of the medium is, for example, about 5 to 8, and the culture is usually carried out at about 20 to 40°C for about 15 to 100 hours, with aeration and stirring as needed. When the host cells are E. coli or yeast, a liquid medium containing nutrients is suitable as the culture medium. The nutrient medium contains, for example, a carbon source, inorganic nitrogen source, or organic nitrogen source necessary for the growth of the transformed host cells. Examples of carbon sources include glucose, dextran, soluble starch, and sucrose, while examples of inorganic or organic nitrogen sources include ammonium salts, nitrates, amino acids, corn slush liquor, peptone, casein, meat extract, soybean meal, and potato extract. The culture medium may optionally contain other nutrients (e.g., inorganic salts (e.g., calcium chloride, sodium dihydrogen phosphate, magnesium chloride), vitamins), antibiotics (e.g., tetracycline, neomycin, ampicillin, kanamycin), etc.). The pH of the culture medium is, for example, about 5 to 8. When the host cell is E. coli, the culture medium can be, for example, LB medium or M9 medium (Molecular Cloning, Cold Spring Harbor Laboratory, Vol. 3, A2.2).The culture is typically carried out at approximately 14-43°C for about 3-24 hours, with aeration and stirring as needed. When the host cells are yeast, for example, Burkholder Minimal Medium (Proc. Natl. Acad. Sci. USA., 1980, Vol. 77, p. 4505) can be used as the culture medium. The culture is typically carried out at approximately 20-35°C for about 14-144 hours, with aeration and stirring as needed. By culturing as described above, the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention can be expressed.
[0112] The production method of the present invention may further include, in addition to the step of culturing transformed host cells of the present invention and expressing anti-TSPAN8-anti-CD3 bispecific antibodies, the step of recovering, isolating, or purifying the anti-TSPAN8-anti-CD3 bispecific antibodies from the transformed host cells. Examples of isolation or purification methods include methods utilizing solubility such as salting out and solvent precipitation, methods utilizing differences in molecular weight such as dialysis, ultrafiltration, and gel filtration, methods utilizing charge such as ion exchange chromatography and hydroxyl apatite chromatography, methods utilizing specific affinity such as affinity chromatography, methods utilizing differences in hydrophobicity such as reverse-phase high-performance liquid chromatography, and methods utilizing differences in isoelectric point such as isoelectric focusing. In one embodiment, the antibody secreted into the culture supernatant can be purified by various chromatography methods, for example, column chromatography using a protein A column or a protein G column.
[0113] The anti-TSPAN8-anti-CD3 bispecific antibody of the present invention also includes anti-TSPAN8-anti-CD3 bispecific antibodies produced by the production method of the present invention.
[0114] <Pharmaceutical compositions, etc., of the bispecific antibody of the present invention> The pharmaceutical compositions of the present invention include a pharmaceutical composition comprising the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention and a pharmaceutically acceptable excipient. The pharmaceutical compositions of the present invention can be prepared by commonly used methods using excipients commonly used in the art, i.e., pharmaceutical excipients and pharmaceutical carriers. Examples of dosage forms of these pharmaceutical compositions include, for example, parenteral preparations such as injections and intravenous infusions, which can be administered by intravenous, subcutaneous, or intraperitoneal administration. In formulation, excipients, carriers, additives, etc., can be used according to these dosage forms, within a pharmaceutically acceptable range.
[0115] The pharmaceutical compositions of the present invention may include post-translational modifications of the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention. For example, pharmaceutical compositions containing antibodies that have undergone either or both of the following: deletion of the C-terminal lysine or pyroglutamylation of the N-terminal region are also included in the present invention.
[0116] In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition containing the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention and / or a post-translational modification of the antibody, selected from (a) and (b) below: (a) A heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody is linked to a primary Fc polypeptide, and the heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 6, and the light chain of an anti-TSPAN8 antibody is linked to a light chain variable region including CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8, and sequence A bispecific antibody comprising a heavy chain variable region of an anti-CD3 antibody containing CDR1 consisting of amino acid sequences 31 to 35 of sequence number 14, CDR2 consisting of amino acid sequences 50 to 68 of sequence number 14, and CDR3 consisting of amino acid sequences 101 to 114 of sequence number 14, and an anti-CD3-scFv region containing a secondary Fc polypeptide linked to a second Fc polypeptide; and an anti-CD3 antibody containing a light chain variable region containing CDR1 consisting of amino acid sequences 168 to 181 of sequence number 14, CDR2 consisting of amino acid sequences 197 to 203 of sequence number 14, and CDR3 consisting of amino acid sequences 236 to 244 of sequence number 14; (b) A heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody is linked to a primary Fc polypeptide, the heavy chain fragment of an anti-TSPAN8 antibody containing a heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10, and a primary Fc polypeptide; a light chain of an anti-TSPAN8 antibody containing a light chain variable region including CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12; and A bispecific antibody comprising a heavy chain variable region of an anti-CD3 antibody containing CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences 101 to 114 of SEQ ID NO: 14, and an anti-CD3-scFv region containing a secondary Fc polypeptide linked to a light chain variable region of an anti-CD3 antibody containing CDR1 consisting of amino acid sequences 168 to 181 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences 197 to 203 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences 236 to 244 of SEQ ID NO: 14.
[0117] In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition containing the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention and / or a post-translational modification of the antibody, selected from (a) and (b) below: (a) A bispecific antibody comprising: a heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody containing a heavy chain variable region consisting of amino acid sequences 1 to 121 of SEQ ID NO: 6 is linked to a primary Fc polypeptide; a light chain of an anti-TSPAN8 antibody containing a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8 is linked to a secondary Fc polypeptide; and a polypeptide comprising an anti-CD3-scFv region containing a heavy chain variable region consisting of amino acid sequences 1 to 125 of SEQ ID NO: 14 and a light chain variable region consisting of amino acid sequences 146 to 254 of SEQ ID NO: 14 is linked to a secondary Fc polypeptide; (b) A bispecific antibody comprising: a heavy chain of an anti-TSPAN8 antibody in which a heavy chain fragment of an anti-TSPAN8 antibody containing a heavy chain variable region consisting of amino acid sequences 1 to 121 of SEQ ID NO: 10 is linked to a first Fc polypeptide; a light chain of an anti-TSPAN8 antibody containing a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 12; and a polypeptide in which an anti-CD3-scFv region containing a heavy chain variable region consisting of amino acid sequences 1 to 125 of SEQ ID NO: 14 and a light chain variable region consisting of amino acid sequences 146 to 254 of SEQ ID NO: 14 is linked to a second Fc polypeptide.
[0118] In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition containing an anti-TSPAN8-anti-CD3 bispecific antibody and / or a post-translational modification of said antibody, comprising: a heavy chain of an anti-TSPAN8 antibody having a heavy chain fragment of an anti-TSPAN8 antibody having an amino acid sequence of SEQ ID NO: 6 linked to a first Fc polypeptide; a light chain of an anti-TSPAN8 antibody having an amino acid sequence of SEQ ID NO: 8; and a polypeptide having an anti-CD3-scFv region having an amino acid sequence of SEQ ID NO: 14 linked to a second Fc polypeptide.
[0119] The amount of the anti-TSPAN8-anti-CD3 bispecific antibody and anti-TSPAN8 antibody added in formulation of the present invention varies depending on the severity and age of the patient's symptoms, the dosage form of the formulation used, and the antibody binding titer, but for example, amounts of approximately 0.001 mg / kg to 100 mg / kg can be used.
[0120] <Pharmaceutical applications of the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention> The anti-TSPAN8-anti-CD3 bispecific antibodies of the present invention, and pharmaceutical compositions containing them, can be used for the treatment of cancer. The present invention also includes a method for treating cancer, comprising the step of administering a therapeutically effective amount of the anti-TSPAN8-anti-CD3 bispecific antibodies of the present invention to a target. Furthermore, the present invention includes the anti-TSPAN8-anti-CD3 bispecific antibodies of the present invention for use in the treatment of cancer. The present invention also includes the use of the anti-TSPAN8-anti-CD3 bispecific antibodies of the present invention in the manufacture of pharmaceutical compositions for the treatment of cancer. The cancers that can be treated according to the present invention are not particularly limited, but include, for example, various peritoneal dissemination cancers, gastric cancer, lung cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell lymphoma, multiple myeloma, T-cell lymphoma and other hematological cancers, myelodysplastic syndromes, adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, anaplastic carcinoma, large cell carcinoma, non-small cell lung cancer, small cell lung cancer, mesothelioma, skin cancer, cutaneous T-cell lymphoma, breast cancer, prostate cancer, bladder cancer, vaginal cancer, cervical cancer, and head cancer. This includes solid cancers such as cervical cancer, uterine cancer, cervix cancer, liver cancer, gallbladder cancer, bile duct cancer, kidney cancer, pancreatic cancer, colon cancer, colorectal cancer, rectal cancer, small intestine cancer, stomach cancer, esophageal cancer, testicular cancer, ovarian cancer, and brain tumors, as well as cancers of bone tissue, cartilage tissue, adipose tissue, muscle tissue, vascular tissue, and hematopoietic tissue. Other examples include sarcomas such as chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant Schwannoma, osteosarcoma, and soft tissue sarcoma, and blastomas such as glioblastoma, glioblastoma multiforme, hepatoblastoma, medulloblastoma, nephroblastoma, neuroblastoma, pancreaticoblastoma, pleuropulmonary blastoma, and retinoblastoma.
[0121] <Anti-TSPAN8 antibody of the present invention> The present invention also provides a novel anti-TSPAN8 antibody or its binding fragment against human TSPAN8, as described below. The anti-TSPAN8 antibody or its antigen-binding fragment provided by the present invention will be collectively referred to as "the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention."
[0122] The present invention provides an anti-TSPAN8 antibody or a binding fragment thereof that selectively binds to human TSPAN8-expressing cancer cells.
[0123] In this specification, "selectively binding to human TSPAN8-expressing cancer cells" means that, when comparing the binding activity of a certain anti-TSPAN8 antibody with that of a commercially available anti-TSPAN8 antibody (TAL69, REA443, etc.) or an anti-TSPAN8 antibody exhibiting a similar binding profile to a commercially available anti-TSPAN8 antibody (e.g., 9F6, 18C10, etc.), the binding strength to TSPAN8 expressed on human TSPAN8-expressing cancer cells is 3 times or more, preferably 5 times or more, and more preferably 10 times or more, compared to the commercially available antibodies, and the binding strength to TSPAN8 expressed on normal cells is 1 / 3 or less, preferably 1 / 5 or less, and more preferably 1 / 10 or less. The binding strength of an antibody to cells can be calculated, for example, using the MFI (Mean Fluorescence Intensity) value obtained by the flow cytometry method shown in Example 1, or the ΔMFI value calculated by subtracting the Isotype MFI from the MFI of each antibody. Furthermore, the binding strength of antibodies to cells can also be measured and calculated by methods commonly used by those skilled in the art, such as ELISA using cancer cells and normal cells. Here, human TSPAN8-expressing cancer cells refer to cancer cells that express human TSPAN8 isolated from cancer patients. In addition to patient-derived peritoneal cancer cells described in Example 1-1, cancer cell lines available from cell banks such as the American Type Culture Collection (ATCC) can be used. As cancer cell lines, for example, in addition to the cell lines established from patient ascites fluid using the method described in Example 1-1, TSPAN8-expressing cell lines such as AGS, KATOIII, SNU5, SNU16, SNU520, ANU719, NCI-N87, HT-29, LoVo, GP2d, AsPC-1, OE19, Li-7Hs746, NUGC-4, OCUM1, and MNK45 can be used. Furthermore, "normal cells" refer to cells derived from normal tissue, and in addition to patient-derived peritoneal mesothelial cells used in Examples 1-5, commercially available primary cultured cells or cell lines such as human peripheral blood mononuclear cells used in Examples 1-3 and cultured peritoneal mesothelial cells used in Examples 1-3 can be used. In one embodiment, the normal cells express TSPAN8. In one embodiment, the normal cells expressing TSPAN8 are patient-derived peritoneal mesothelial cells and cultured peritoneal mesothelial cells used in Examples 1-3. In one embodiment, the normal cells do not express TSPAN8. In one embodiment, the normal cells that do not express TSPAN8 are human peripheral blood mononuclear cells used in Examples 1-3.
[0124] The present invention also provides an anti-TSPAN8 antibody or an antigen-binding fragment thereof that recognizes a portion of the TSPAN8 protein as an epitope. In one embodiment, the epitope is a structural unit consisting of an amino acid sequence contained in the LEL region of TSPAN8. In one embodiment, the epitope is a structural unit consisting of a portion of the TSPAN8 protein represented by the amino acid sequence from 126 to 155 of SEQ ID NO: 2. In one embodiment, the epitope is a structural unit consisting of one or more amino acid sequences contained in a portion of the TSPAN8 protein represented by the amino acid sequence from 126 to 155 of SEQ ID NO: 2. In one embodiment, the epitope is a structural unit containing at least amino acid number 131 of SEQ ID NO: 2.
[0125] In one embodiment, the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention binds to at least one amino acid present in the human TSPAN8 region from amino acid numbers 126 to 155 of SEQ ID NO: 2. In one embodiment, the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention binds to at least one amino acid present in the human TSPAN8 region from amino acid numbers 126 to 155 of SEQ ID NO: 2 and selectively binds to human TSPAN8-expressing cancer cells.
[0126] In one embodiment, the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention binds to at least the amino acid at amino acid number 131 of SEQ ID NO: 2, which is located in the human TSPAN8 region from amino acid numbers 126 to 155 of SEQ ID NO: 2. In one embodiment, the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention binds to at least the amino acid at amino acid number 131 of SEQ ID NO: 2, which is located in the human TSPAN8 region from amino acid numbers 126 to 155 of SEQ ID NO: 2, and selectively binds to human TSPAN8-expressing cancer cells.
[0127] Whether or not an anti-TSPAN8 antibody or its antigen-binding fragment binds to an amino acid in the human TSPAN8 region from amino acid numbers 126 to 155 of SEQ ID NO: 2 (for example, the amino acid at amino acid number 131 of SEQ ID NO: 2) can be confirmed using the epitope identification method described in Examples 4-1 and 4-2 of this application.
[0128] The present invention also provides an anti-TSPAN8 antibody or its antigen-binding fragment as shown in (a) and (b) below: (a) An anti-TSPAN8 antibody or its antigen-binding fragment comprising a heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 4, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 4, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 4, and a light chain variable region including CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (b) An anti-TSPAN8 antibody or its antigen-binding fragment comprising a heavy chain variable region including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10, and a light chain variable region including CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12.
[0129] In one embodiment, the anti-TSPAN8 antibody or antigen-binding fragment of the present invention is an anti-TSPAN8 antibody or antigen-binding fragment selected from (a) and (b) below: (a) An anti-TSPAN8 antibody or its antigen-binding fragment comprising a heavy chain variable region consisting of amino acid sequences from amino acid numbers 1 to 121 of SEQ ID NO: 4, and a light chain variable region consisting of amino acid sequences from amino acid numbers 1 to 107 of SEQ ID NO: 8; (b) An anti-TSPAN8 antibody or its antigen-binding fragment or its antigen-binding fragment, comprising a heavy chain variable region consisting of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 10, and a light chain variable region consisting of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO: 12.
[0130] The heavy chain constant region of the anti-TSPAN8 antibody of the present invention can be selected from any of the Igγ, Igμ, Igα, Igδ, or Igε constant regions. For example, Igγ can be selected from Igγ1, Igγ2, Igγ3, or Igγ4. In one embodiment, the heavy chain constant region is the Igγ1 constant region, for example, the human Igγ1 constant region. The heavy chain constant region of the anti-TSPAN8 antibody of the present invention may also contain amino acid mutations such as LALA mutations to reduce ADCC and CDC. The light chain constant region of the anti-TSPAN8 antibody of the present invention can be selected from any of the Igλ or Igκ constant regions. In one embodiment, the light chain constant region is the Igκ constant region, for example, the human Igκ constant region.
[0131] In one embodiment, the antigen-binding fragment of the anti-TSPAN8 antibody of the present invention is scFv, Fab, Fab', F(ab')2, or a single-arm antibody.
[0132] In one embodiment, the anti-TSPAN8 antibody of the present invention is an anti-TSPAN8 antibody selected from (a) and (b) below: (a) An anti-TSPAN8 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 4 and a light chain consisting of the amino acid sequence of SEQ ID NO: 8; (b) An anti-TSPAN8 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 10 and a light chain consisting of the amino acid sequence of SEQ ID NO: 12.
[0133] The present invention also provides anti-TSPAN8 antibodies or their antigen-binding fragments (collectively referred to as "the competitive anti-TSPAN8 antibodies of the present invention") as shown in (a) to (d) below: (a) An anti-TSPAN8 antibody or its antigen-binding fragment that competes with an anti-TSPAN8 antibody containing a heavy chain variable region consisting of amino acid sequences 1 to 121 of SEQ ID NO: 4 and a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8 for binding to human TSPAN8-expressing cancer cells; (b) An anti-TSPAN8 antibody or its antigen-binding fragment that competes with an anti-TSPAN8 antibody containing a heavy chain variable region consisting of amino acid sequences 1 to 121 of SEQ ID NO: 10 and a light chain variable region consisting of amino acid sequences 1 to 107 of SEQ ID NO: 12 for binding to human TSPAN8-expressing cancer cells; (c) An anti-TSPAN8 antibody or its antigen-binding fragment that competes with an anti-TSPAN8 antibody containing a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 34 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 36 for binding to human TSPAN8-expressing cancer cells; (d) An anti-TSPAN8 antibody or its antigen-binding fragment that competes with an anti-TSPAN8 antibody containing a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 35 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 37 for binding to human TSPAN8-expressing cancer cells.
[0134] The competitive anti-TSPAN8 antibody of the present invention can be obtained by a person skilled in the art, for example, by obtaining an antibody against human TSPAN8 using known antibody production techniques with human TSPAN8-expressing cells as the antigen, and then performing a competitive test on the obtained antibody regarding its binding to human TSPAN8-expressing cells with a competing anti-TSPAN8 antibody. For the competitive test, a method known to a person skilled in the art, such as flow cytometry, can be used, and for example, the competitive test using human TSPAN8-expressing cancer cells described in Example 4-3 can be used. Various cells as described above can be used as human TSPAN8-expressing cancer cells for the competitive test.
[0135] In one embodiment, the anti-TSPAN8 antibody or antigen-binding fragment of the present invention is an anti-TSPAN8 antibody or antigen-binding fragment selected from either (a) or (b) below: (a) An anti-TSPAN8 antibody or its antigen-binding fragment that competes with an anti-TSPAN8 antibody containing a heavy chain consisting of the amino acid sequence of SEQ ID NO: 4 and a light chain consisting of the amino acid sequence of SEQ ID NO: 8 for binding to human TSPAN8-expressing cancer cells. (b) An anti-TSPAN8 antibody or its antigen-binding fragment that competes with an anti-TSPAN8 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 10 and a light chain consisting of the amino acid sequence of SEQ ID NO: 12 for binding to human TSPAN8-expressing cancer cells.
[0136] In one embodiment, the anti-TSPAN8 antibody or antigen-binding fragment of the present invention is an anti-TSPAN8 antibody or antigen-binding fragment selected from either (c) or (d) below: (c) An anti-TSPAN8 antibody or its antigen-binding fragment that competes with an anti-TSPAN8 antibody containing a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 34 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 36 for binding to human TSPAN8-expressing cancer cells. (d) An anti-TSPAN8 antibody or its antigen-binding fragment that competes with an anti-TSPAN8 antibody containing a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 35 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 37 for binding to human TSPAN8-expressing cancer cells.
[0137] <Other bispecific antibodies of the present invention> The present invention provides a bispecific antibody comprising an anti-TSPAN8 antibody or its antigen-binding fragment linked to an antibody against a surface antigen of T cells or natural killer (NK) cells, or the antigen-binding fragment thereof. The shape of the bispecific antibody is not particularly limited and can take various shapes of antibodies that are commonly used by those skilled in the art, such as those described in Non-Patent Documents 3 or 4.
[0138] The present invention also provides the following bispecific antibodies: A bispecific antibody that binds to TSPAN8 and the surface antigen of T cells or NK cells, (a) The Fab region of the anti-TSPAN8 antibody comprising a heavy chain fragment containing the heavy chain variable region of the anti-TSPAN8 antibody of the present invention and a light chain containing the light chain variable region of the anti-TSPAN8 antibody of the present invention, (b) scFv region of antibody against T cell or NK cell surface antigen, including heavy chain variable region and light chain variable region of antibody against T cell or NK cell surface antigen, and (c) The Fc region consists of a first Fc polypeptide linked to the heavy chain fragment of the Fab region of (a) and a second Fc polypeptide linked to the scFv region of (b), A bispecific antibody consisting of the following components.
[0139] Other bispecific antibodies of the present invention can be prepared by those skilled in the art using the method described in Non-Patent Document 4 or by general methods with reference to the description of <Anti-TSPAN8-Anti-CD3 Bispecific Antibody of the Present Invention>. Many antibodies against surface antigens of T cells or NK cells are known to date (Current Opinion in Biotechnology, 2020, Vol. 65, pp. 9-16), and the sequence information of these antibodies can be used. Embodiments of other bispecific antibodies of the present invention are as described in <Anti-TSPAN8-Anti-CD3 Bispecific Antibody of the Present Invention>, except that the scFv region of the anti-CD3 antibody is used. Other bispecific antibodies of the present invention can also be used in the treatment of cancer.
[0140] In one embodiment, the antibody or antigen-binding fragment of the other bispecific antibody of the present invention against a T cell or NK cell surface antigen is an antibody or antigen-binding fragment of a T cell or NK cell surface antigen. In one embodiment, the antibody or antigen-binding fragment of the T cell or NK cell surface antigen is an anti-CD3 antibody, an anti-CD137 antibody, an anti-PD-1 (Programmed cell Death - 1) antibody, an anti-PD-L1 (Programmed cell Death - 1) antibody, an anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) antibody, an anti-CD16 antibody, an anti-NKG2D (Natural Killer Group 2, member D) antibody, or an antigen-binding fragment thereof. In one embodiment, the antibody or antigen-binding fragment of the T cell is an anti-CD3 antibody or an antigen-binding fragment. In one embodiment, the antigen-binding fragment of the anti-CD3 antibody is an scFv of the anti-CD3 antibody.
[0141] <The fusion, complex, and cells expressing the anti-TSPAN8 antibody or its antigen-binding fragment on the cell surface of the present invention> The present invention also provides an anti-TSPAN8 antibody or its antigen-binding fragment (also referred to as "the fusion of the present invention") linked to other proteins (including antibodies) or polypeptides other than TSPAN8. The proteins and polypeptides used in the fusion of the present invention are not particularly limited, and for example, various antibodies, cytokines, chemokines, human serum albumin, various tag peptides, artificial helix motif peptides, maltose-binding proteins, glutathione S-transferase, and other peptides or proteins that can promote polymerization may be used. In one embodiment of the fusion of the present invention, a protein or polypeptide is linked to the anti-TSPAN8 antibody or its antigen-binding fragment. In one embodiment, the protein or polypeptide used in the fusion of the present invention may be, for example, an antibody or its antigen-binding fragment against surface antigens of immune cells such as granulocytes and natural killer T (NKT) cells, blood cells such as dendritic cells and macrophages, or a polypeptide that activates immune cells such as various interleukins (e.g., IL-2, IL-7, IL-12, IL-15). In this case, the protein or polypeptide used in the fusion of the present invention may be directly linked to the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention, or it may be linked via any linker (e.g., a peptide linker).
[0142] The present invention also provides an anti-TSPAN8 antibody or its antigen-binding fragment (also referred to as "the complex of the present invention") to which carbohydrates, lipids, metals (including radioisotopes), organic compounds (including toxins, near-infrared fluorescent dyes, chelating agents), etc. (also referred to as "modifiers") are bound. In this specification, "modifier" refers to a non-peptide substance that is directly bound to the antibody or its antigen-binding fragment or via a linker, etc. The modifiers used in the complex of the present invention are not particularly limited and include, for example, polyethylene glycol, sugar chains, phospholipids, radioisotopes (e.g., zirconium-89( 89 Zr), Yttrium-90 ( 90 Y), Indium-111 ( 111 In), Astatine-211 (211 At), Actinium-225 ( 225 Examples of modifiers include Ac), organic compounds, toxins, near-infrared fluorescent dyes (e.g., IRDye®), and chelating agents. The modifier used in the complex may be directly bound to the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention, or it may be bound via any linker. In one embodiment, the complex of the present invention is an antibody-drug conjugate (ADC) of an anti-TSPAN8 antibody or its antigen-binding fragment. The drug and linker used in the ADC may be selected from among drugs and linkers commonly used by those skilled in the art. In one embodiment, the complex of the present invention is a radioisotope-labeled antibody to which a radioisotope is bound to the anti-TSPAN8 antibody or its antigen-binding fragment.
[0143] The present invention also provides cells (e.g., Chimeric antigen receptor-T cells; CAR-T cells) expressing the anti-TSPAN8 antibody or its antigen-binding fragment on the cell surface. Such cells can be prepared by those skilled in the art using polynucleotides encoding the anti-TSPAN8 antibody or its antigen-binding fragment. Various immune cells (T cells, NK cells, NKT cells, etc.) can be used to express the anti-TSPAN8 antibody or its antigen-binding fragment.
[0144] Cells expressing the anti-TSPAN8 antibody or its antigen-binding fragment, the fusion of the present invention, the complex of the present invention, or the anti-TSPAN8 antibody or its antigen-binding fragment on their cell surface bind to human TSPAN8 (gene number: NM_004616.2). Binding to human TSPAN8 can be confirmed using known methods for measuring binding activity. Examples of methods for measuring binding activity include ELISA and flow cytometry. When using ELISA, for example, the method described in Example 8 can be used, and when using flow cytometry, for example, the method described in Example 1 can be used.
[0145] In one embodiment, the anti-TSPAN8 antibody or its antigen-binding fragment, the fusion and complex of the present invention, and the antibody or antigen-binding fragment portion in cells expressing the anti-TSPAN8 antibody or its antigen-binding fragment on the cell surface may be post-translationally modified. In one embodiment, the post-translation modification is pyroglutamylation of the N-terminus of the heavy chain variable region and / or lysine deletion at the C-terminus of the heavy chain.
[0146] The anti-TSPAN8 antibody or its antigen-binding fragment of the present invention, the fusion of the present invention, and the complex of the present invention, as well as cells expressing the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention on the cell surface, can be prepared by those skilled in the art using methods known in the art, based on the VH and VL sequence information of the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention disclosed herein, other peptides or proteins (e.g., antibodies) used in the fusion of the present invention, and information on modifiers used in the complex of the present invention. The anti-TSPAN8 antibody or its antigen-binding fragment of the present invention can be produced, for example, by the method described in the section <Method for producing the bispecific antibody of the present invention>.
[0147] <Polynucleotides, expression vector, host cells, and production method of the anti-TSPAN8 antibody of the present invention> The present invention also provides the polynucleotides described in (1) to (4) below: (1) A polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention. (2) A polynucleotide comprising a base sequence encoding the light chain variable region of the anti-TSPAN8 antibody of the present invention or its antigen-binding fragment, (3) A polynucleotide comprising the base sequence encoding the heavy chain of the anti-TSPAN8 antibody of the present invention, (4) A polynucleotide comprising a base sequence encoding the light chain of the anti-TSPAN8 antibody of the present invention.
[0148] In one embodiment of the polynucleotide described in (1) above, the polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention is a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody, including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 4, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 4, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 4; (b) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody, which includes CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10.
[0149] In one embodiment of the polynucleotide described in (1) above, the polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention is a polynucleotide selected from (a) and (b) below: (a) A polynucleotide containing a nucleotide sequence that encodes the heavy chain variable region of an anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 4; (b) A polynucleotide containing a base sequence that encodes the heavy chain variable region of the anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 10.
[0150] In one embodiment of the polynucleotide described in (2) above, the polynucleotide comprising a nucleotide sequence encoding the light chain variable region of the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention is a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody, including CDR1 consisting of amino acid sequences from amino acid numbers 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences from amino acid numbers 89 to 96 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody, which includes CDR1 consisting of amino acid sequences from amino acid numbers 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences from amino acid numbers 89 to 96 of SEQ ID NO: 12.
[0151] In one embodiment of the polynucleotide described in (2) above, the polynucleotide comprising a nucleotide sequence encoding the light chain variable region of the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention is a polynucleotide selected from (a) or (b) below: (a) A polynucleotide containing a base sequence that encodes the light chain variable region of an anti-TSPAN8 antibody consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8; (b) A polynucleotide containing a base sequence that encodes the light chain variable region of the anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO. 12.
[0152] In one embodiment of the polynucleotide described in (3) above, the polynucleotide containing the base sequence encoding the heavy chain of the anti-TSPAN8 antibody of the present invention is a polynucleotide selected from (a) or (b) below: (a) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 4; (b) A polynucleotide containing a base sequence that encodes the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 10.
[0153] In one embodiment of the polynucleotide described in (4) above, the polynucleotide comprising the base sequence encoding the light chain of the anti-TSPAN8 antibody of the present invention is a polynucleotide selected from (a) or (b) below: (a) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in Sequence ID No. 8; (b) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in Sequence ID No. 12.
[0154] The polynucleotides described in this section can be prepared by a person skilled in the art using methods known in the art, based on their base sequences.
[0155] The present invention also provides an expression vector (also referred to as "an expression vector for the anti-TSPAN8 antibody of the present invention") comprising one or more polynucleotides from among those described in (1) to (4) below. Each expression vector may contain one or more of each polynucleotide. (1) A polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-TSPAN8 antibody or its antigen-binding fragment of the present invention, (2) A polynucleotide comprising a base sequence encoding the light chain variable region of the anti-TSPAN8 antibody of the present invention or its antigen-binding fragment, (3) A polynucleotide comprising the base sequence encoding the heavy chain of the anti-TSPAN8 antibody of the present invention, (4) A polynucleotide comprising a base sequence encoding the light chain of the anti-TSPAN8 antibody of the present invention.
[0156] In one embodiment of the expression vector for the anti-TSPAN8 antibody of the present invention, which comprises the polynucleotide described in (1) above, the expression vector comprises a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody, including CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 4, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 4, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 4; (b) A polynucleotide comprising the heavy chain variable region of an anti-TSPAN8 antibody, which includes CDR1 consisting of the amino acid sequence from amino acid numbers 31 to 35 of SEQ ID NO: 10, CDR2 consisting of the amino acid sequence from amino acid numbers 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of the amino acid sequence from amino acid numbers 99 to 110 of SEQ ID NO: 10.
[0157] In one embodiment of the expression vector for the anti-TSPAN8 antibody of the present invention, which comprises the polynucleotide described in (1) above, the expression vector comprises a polynucleotide selected from (a) and (b) below: (a) A polynucleotide containing a nucleotide sequence that encodes the heavy chain variable region of an anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 4; (b) A polynucleotide containing a base sequence that encodes the heavy chain variable region of the anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 10.
[0158] In one embodiment of the expression vector for the anti-TSPAN8 antibody of the present invention, which comprises the polynucleotide described in (2) above, the expression vector comprises a polynucleotide selected from (a) and (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody, including CDR1 consisting of amino acid sequences from amino acid numbers 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences from amino acid numbers 89 to 96 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody, which includes CDR1 consisting of amino acid sequences from amino acid numbers 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences from amino acid numbers 89 to 96 of SEQ ID NO: 12.
[0159] In one embodiment of the expression vector for the anti-TSPAN8 antibody of the present invention, which comprises the polynucleotide described in (2) above, the expression vector comprises a polynucleotide selected from (a) or (b) below: (a) A polynucleotide containing a base sequence that encodes the light chain variable region of an anti-TSPAN8 antibody consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8; (b) A polynucleotide containing a base sequence that encodes the light chain variable region of the anti-TSPAN8 antibody, consisting of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO. 12.
[0160] In one embodiment of the expression vector for the anti-TSPAN8 antibody of the present invention, which comprises the polynucleotide described in (3) above, the expression vector comprises a polynucleotide selected from (a) or (b) below: (a) A polynucleotide containing a base sequence encoding the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 4; (b) A polynucleotide containing a base sequence that encodes the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 10.
[0161] In one embodiment of the expression vector for the anti-TSPAN8 antibody of the present invention, which comprises the polynucleotide described in (4) above, the expression vector comprises a polynucleotide selected from (a) or (b) below: (a) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in Sequence ID No. 8; (b) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in Sequence ID No. 12.
[0162] In one embodiment, the expression vector for the anti-TSPAN8 antibody of the present invention is an expression vector comprising a polynucleotide selected from (a) or (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody, comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 4, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 4, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 4; and a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody, comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10; and a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12.
[0163] In one embodiment, the expression vector for the anti-TSPAN8 antibody of the present invention is an expression vector comprising a polynucleotide selected from (a) or (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody consisting of amino acid sequences 1 to 121 of SEQ ID NO: 4, and a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 10, and a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO: 12.
[0164] In one embodiment, the expression vector for the anti-TSPAN8 antibody of the present invention is an expression vector comprising a polynucleotide selected from (a) or (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 4, and a polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 8; (b) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 10, and a polynucleotide comprising a base sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 12.
[0165] The expression vectors described in this section can be prepared by those skilled in the art in accordance with the method described above for the <Expression Vectors for Bispecific Antibodies of the Present Invention>.
[0166] The present invention also provides host cells transformed with an expression vector containing the following polynucleotides (1) to (4) (also referred to as "host cells for the anti-TSPAN8 antibody of the present invention"). The host cells for the anti-TSPAN8 antibody of the present invention may contain one or more of each of the following polynucleotides (1) to (4) as a result of transformation with the expression vector for the anti-TSPAN8 antibody of the present invention. (1) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of the anti-TSPAN8 antibody or an antigen-binding fragment thereof of the present invention (2) A polynucleotide comprising a nucleotide sequence encoding the light chain variable region of the anti-TSPAN8 antibody or an antigen-binding fragment thereof of the present invention, (3) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of the anti-TSPAN8 antibody of the present invention, (4) A polynucleotide comprising a nucleotide sequence encoding the light chain of the anti-TSPAN8 antibody of the present invention.
[0167] In one embodiment of the host cell for the anti-TSPAN8 antibody of the present invention comprising the polynucleotide of (1) above, the host cell comprises a polynucleotide selected from the following (a) and (b): (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody comprising a CDR1 consisting of the amino acid sequence from amino acid number 31 to 35 of SEQ ID NO: 4, a CDR2 consisting of the amino acid sequence from amino acid number 50 to 66 of SEQ ID NO: 4, and a CDR3 consisting of the amino acid sequence from amino acid number 99 to 110 of SEQ ID NO: 4; (b) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody comprising a CDR1 consisting of the amino acid sequence from amino acid number 31 to 35 of SEQ ID NO: 10, a CDR2 consisting of the amino acid sequence from amino acid number 50 to 66 of SEQ ID NO: 10, and a CDR3 consisting of the amino acid sequence from amino acid number 99 to 110 of SEQ ID NO: 10.
[0168] In one embodiment of the host cell for the anti-TSPAN8 antibody of the present invention comprising the polynucleotide of (1) above, the host cell comprises a polynucleotide selected from the following (a) and (b): (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid number 1 to 121 of SEQ ID NO: 4; (b) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid number 1 to 121 of SEQ ID NO: 10.
[0169] In one embodiment of the host cell for the anti-TSPAN8 antibody of the present invention comprising the polynucleotide of (2) above, the host cell comprises a polynucleotide selected from the following (a) and (b): (a) A polynucleotide comprising a base sequence encoding a light chain variable region of an anti-TSPAN8 antibody comprising CDR1 consisting of the amino acid sequence from amino acid number 24 to 34 of SEQ ID NO: 8, CDR2 consisting of the amino acid sequence from amino acid number 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of the amino acid sequence from amino acid number 89 to 96 of SEQ ID NO: 8; (b) A polynucleotide comprising a base sequence encoding a light chain variable region of an anti-TSPAN8 antibody comprising CDR1 consisting of the amino acid sequence from amino acid number 24 to 34 of SEQ ID NO: 12, CDR2 consisting of the amino acid sequence from amino acid number 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of the amino acid sequence from amino acid number 89 to 96 of SEQ ID NO: 12.
[0170] In one embodiment of the host cell for the anti-TSPAN8 antibody of the present invention comprising the polynucleotide of (2) above, the host cell comprises a polynucleotide selected from the following (a) or (b): (a) A polynucleotide comprising a base sequence encoding a light chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid number 1 to 107 of SEQ ID NO: 8; (b) A polynucleotide comprising a base sequence encoding a light chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid number 1 to 107 of SEQ ID NO: 12.
[0171] In one embodiment of the host cell for the anti-TSPAN8 antibody of the present invention comprising the polynucleotide of (3) above, the host cell comprises a polynucleotide selected from the following (a) or (b): (a) A polynucleotide comprising a base sequence encoding a heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 4; (b) A polynucleotide containing the base sequence that encodes the heavy chain of the anti-TSPAN8 antibody, which consists of the amino acid sequence shown in Sequence ID No. 10.
[0172] In one embodiment of a host cell for the anti-TSPAN8 antibody of the present invention, comprising the polynucleotide described in (4) above, the host cell comprises a polynucleotide selected from (a) or (b) below: (a) A polynucleotide containing the base sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in Sequence ID No. 8; (b) A polynucleotide containing the base sequence that encodes the light chain of the anti-TSPAN8 antibody, which consists of the amino acid sequence shown in Sequence ID No. 12.
[0173] In one embodiment, the host cell for the anti-TSPAN8 antibody of the present invention comprises a polynucleotide selected from (a) or (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody, comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 4, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 4, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 4; and a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody, comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 8, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody comprising CDR1 consisting of amino acid sequences 31 to 35 of SEQ ID NO: 10, CDR2 consisting of amino acid sequences 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of amino acid sequences 99 to 110 of SEQ ID NO: 10; and a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody comprising CDR1 consisting of amino acid sequences 24 to 34 of SEQ ID NO: 12, CDR2 consisting of amino acid sequences 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of amino acid sequences 89 to 96 of SEQ ID NO: 12.
[0174] In one embodiment, the host cell for the anti-TSPAN8 antibody of the present invention is a host cell containing a polynucleotide selected from (a) or (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody consisting of amino acid sequences 1 to 121 of SEQ ID NO: 4, and a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody consisting of amino acid sequences 1 to 107 of SEQ ID NO: 8; (b) A polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid numbers 1 to 121 of SEQ ID NO: 10, and a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of an anti-TSPAN8 antibody consisting of the amino acid sequence from amino acid numbers 1 to 107 of SEQ ID NO: 12.
[0175] In one embodiment, the host cell for the anti-TSPAN8 antibody of the present invention is a host cell containing a polynucleotide selected from (a) or (b) below: (a) A polynucleotide comprising a nucleotide sequence encoding the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 4, and a polynucleotide comprising a nucleotide sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 8; (b) A polynucleotide comprising a base sequence encoding the heavy chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 10, and a polynucleotide comprising a base sequence encoding the light chain of an anti-TSPAN8 antibody consisting of the amino acid sequence shown in SEQ ID NO: 12.
[0176] The host cells described in this section can be prepared by those skilled in the art in accordance with the method described above for the transformed host cells of the present invention.
[0177] The present invention further provides a method for producing an anti-TSPAN8 antibody or its antigen-binding fragment, comprising the step of culturing host cells for the anti-TSPAN8 antibody of the present invention. This method can be carried out by those skilled in the art in accordance with the method for producing a bispecific antibody of the present invention described above.
[0178] <Pharmaceutical applications of the anti-TSPAN8 antibody and other materials of the present invention> The present invention also provides a pharmaceutical composition comprising the anti-TSPAN8 antibody or its antigen-binding fragment, a fusion of the present invention, a complex of the present invention, and cells expressing the anti-TSPAN8 antibody or its antigen-binding fragment on the cell surface (collectively referred to as "the anti-TSPAN8 antibody, etc." in this section), and a pharmaceutically acceptable excipient. The pharmaceutical composition can be used for the treatment of cancer. The present invention also provides a method for treating cancer, comprising the step of administering a therapeutically effective amount of the anti-TSPAN8 antibody, etc. of the present invention, the anti-TSPAN8 antibody, etc. of the present invention for use in the treatment of cancer, and the use of the anti-TSPAN8 antibody, etc. of the present invention in the manufacture of a pharmaceutical composition for the treatment of cancer. The pharmaceutical uses of the anti-TSPAN8 antibody, etc. of the present invention can be carried out by those skilled in the art in accordance with the description of <The pharmaceutical composition, etc. of the bispecific antibody of the present invention> above. Cancers targeted for treatment by the pharmaceutical uses of the anti-TSPAN8 antibody, etc. of the present invention include the cancers described in <The pharmaceutical composition, etc. of the bispecific antibody of the present invention> above.
[0179] <Anti-CD3 antibody of the present invention> The present invention also provides an anti-CD3 antibody or its antigen-binding fragment as shown below: An anti-CD3 antibody or its antigen-binding fragment comprising a heavy chain variable region including CDR1 consisting of amino acid sequences from amino acid numbers 31 to 35 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences from amino acid numbers 50 to 68 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences from amino acid numbers 101 to 114 of SEQ ID NO: 14, and a light chain variable region including CDR1 consisting of amino acid sequences from amino acid numbers 168 to 181 of SEQ ID NO: 14, CDR2 consisting of amino acid sequences from amino acid numbers 197 to 203 of SEQ ID NO: 14, and CDR3 consisting of amino acid sequences from amino acid numbers 236 to 244 of SEQ ID NO: 14.
[0180] In one embodiment, the anti-CD3 antibody or antigen-binding fragment of the present invention is an anti-CD3 antibody or antigen-binding fragment comprising a heavy chain variable region consisting of the amino acid sequence from amino acid numbers 1 to 125 of SEQ ID NO: 14 and a light chain variable region consisting of the amino acid sequence from amino acid numbers 146 to 254 of SEQ ID NO: 14.
[0181] In one embodiment, the antigen-binding fragment of the anti-CD3 antibody of the present invention is an scFv. In one embodiment, the antigen-binding fragment of the anti-CD3 antibody of the present invention is an anti-CD3 antibody scFv comprising a heavy chain variable region consisting of the amino acid sequence from amino acid numbers 1 to 125 of SEQ ID NO: 14 and a light chain variable region consisting of the amino acid sequence from amino acid numbers 146 to 254 of SEQ ID NO: 14. In one embodiment, the antigen-binding fragment of the anti-CD3 antibody of the present invention is an anti-CD3 antibody scFv consisting of the amino acid sequence from amino acid numbers 1 to 254 of SEQ ID NO: 14.
[0182] The anti-CD3 antibody or antigen-binding fragment thereof of the present invention can be prepared by those skilled in the art by referring to the descriptions in this specification, such as <the anti-TSPAN8-anti-CD3 bispecific antibody of the present invention>. The anti-CD3 antibody or antigen-binding fragment thereof of the present invention can be confirmed using known binding activity measurement methods. The anti-CD3 antibody or antigen-binding fragment thereof of the present invention can be used, for example, in a bispecific antibody with an antibody against a tumor antigen, which is used in the treatment of cancer.
[0183] Specific examples are provided herein for further understanding of the present invention, but these are for illustrative purposes only and do not limit the present invention.
Example
[0184] [Example 1: Obtaining an antibody that selectively binds to an antigen expressed on cancer peritoneal dissemination cells] [Example 1-1: Obtaining cancer peritoneal dissemination cells derived from patients] Cancer peritoneal seeding cells were obtained from patients by the following method. The acquisition of cancer peritoneal seeding cells from patients was carried out according to the method described in the literature "Establishment of cell lines of peritoneal metastatic cancer (gastric, pancreatic, ovarian cancer, etc.)" by Fumiko Chikuwaki and Hiroki Sasaki (edited by Hiroki Sasaki, "Guide to Cancer Research Practice Using Patient-Derived Cancer Models", Yodosha, 2019, pp. 28-37). Ascites collected from patients was dispensed into a 50 mL centrifuge tube (Sumitomo Bakelite Co., Ltd., MS-52550, hereinafter referred to as "50 mL centrifuge tube") of ProteoSave (registered trademark) SS and centrifuged at room temperature at 430×g for 3 minutes. After removing the supernatant, hemolysis buffer was added to the precipitate and hemolyzed at room temperature for 10 to 20 minutes. The hemolysis buffer was prepared by filtering 17 mM Tris-HCL (pH 7.65) containing 0.75% ammonium chloride through a filter with a pore size of 0.22 μm. After centrifugation, the supernatant was removed, and 50 mL of Dulbecco's PBS(-) (Nissui Pharmaceutical Co., Ltd., 05913, hereinafter referred to as "PBS(-)") was added to wash the cells. Then, the cells were recovered by centrifugation at room temperature at 430×g for 3 minutes. All cells in the collected ascites were resuspended in RPMI-1640 medium (containing L-glutamine) (FUJIFILM Wako Pure Chemical Corporation, 189-02025) containing 10% FBS (Thermo Fisher Scientific, 10270-106) and ×1 Antibiotic-Antimycotic (Thermo Fisher Scientific, 15240062). (Hereinafter, the medium after adding FBS, etc. is referred to as "RPMI-1640 medium".) 6 ~1×10 7 cells per 10 mL were seeded and cultured in a 37°C, 5% CO2 incubator. Cells in ascites fluid include both adherent and suspension cells. Adherent cells include not only cancer cells but also non-cancer cells (fibroblasts, peritoneal mesothelial cells, etc.). By utilizing the property that non-cancer cells detach more quickly than cancer cells, these cells were isolated from all cells in the ascites fluid. Specifically, the dish in which all the cells in the ascites fluid were cultured was washed with PBS(-), and then treated with 2 mL of 0.05% trypsin-EDTA (Thermo Fisher Scientific, 15400054) for several minutes to detach the non-cancer cells. The non-cancer cells contained in the detached cells were continued to be cultured in a new dish and used in Examples 1-5. After removing non-cancer cells, the cancer cells were allowed to proliferate to approximately 80% confluence of the dish area. This process of subculturing half of the cells into a new dish was repeated, and cells that underwent five or more subculturings were classified as adherent cancer cells. For suspension cells, 5 mL of culture supernatant and 5 mL of RPMI-1640 medium from the culture dish were seeded into a new 100 mm dish and subculturised five or more times to be classified as suspension cancer cells. If cancer peritoneal dissemination cells from a single patient contained both adherent and suspension cancer cells during proliferation, these were classified as mixed cancer cells. In this specification, adherent cancer cells, suspension cancer cells, or mixed cancer cells isolated from ascites fluid collected from patients by the above method are collectively referred to as "cancer peritoneal dissemination cells." The 12 cells obtained (NSC-7C, NSC-9C, NSC-10C, NSC-14C, NSC-15CF, NSC-16C, NSC-20C, NSC-22C, NSC-24C, NSC-32C, NSC-34C, and NSC-35C-1 (hereinafter also referred to as "12 types of cancer peritoneal dissemination cells")) were used in subsequent studies.
[0185] [Examples 1-2: Preparation of anti-gastric cancer antigen antibody-producing hybridomas] Using the biomonoclonal antibody development technology "VelocImmune" (registered trademark) antibody technology; Regeneron (US Patent No. 6596541)) mice, we obtained an anti-gastric cancer antigen antibody that binds to cancer peritoneal dissemination cells. From the cancer peritoneal dissemination cells obtained in Example 1-1, NSC-10C, NSC-35C-1, NSC-24C, NSC-7C, NSC-14C, and NSC-34C were divided into groups of 3 cells each and mixed. These were then suspended in TiterMax® Gold ADJUVANT (MERCK, T2684) or PBS(-) to prepare a cancer peritoneal dissemination cell suspension. This suspension was immunized to velocimune mice, and hybridomas were produced according to a standard procedure. Single colonies of hybridomas were isolated using an automated picking device, and monoclonal hybridoma cells (hereinafter referred to as "clones") were obtained. The isolated clones were cultured at 37°C in an 8% CO2 incubator, and the supernatant after 4 days of culture was collected in a 96-well plate and used in the following experiments.
[0186] [Examples 1-3: Selection of anti-gastric cancer antigen antibodies that selectively bind to cancer peritoneal dissemination cells] 1. Confirmation of binding of anti-gastric cancer antigen antibodies to cancer peritoneal dissemination cells and EpCAM-expressing cells. The cell supernatant of the clones obtained in Example 1-2 contains antibodies (hereinafter referred to as "antibodies contained in the clone supernatant"). First, the binding of antibodies contained in the clonal supernatant to 12 types of cancer peritoneal dissemination cells obtained in Example 1-1 was measured by flow cytometry, and clones that produced antibodies that strongly bound to cancer peritoneal dissemination cells were selected. BV421 Goat Anti-Mouse Ig (Becton, Dickinson and Company, 563846) was used for flow cytometry. Next, in order to exclude clones that provide antibodies that bind to the cancer antigen EpCAM, the binding of antibodies contained in the clonal supernatant to human EpCAM-Myc-DDK expressing CHO-K1 cells was measured. Human EpCAM-Myc-DDK expressing CHO-K1 cells were prepared by transfecting CHO-K1 cells (ATCC, CCL-61) with EPCAM (Myc-DDK-tagged)-Human epithelial cell adhesion molecule (EPCAM) (ORIGENE, RC201989). The binding of these cells to antibodies contained in the clonal supernatant was measured by flow cytometry. Flow cytometry was performed using BV421 Goat Anti-Mouse Ig. To select clones that provided supernatant without binding activity to EpCAM-expressing cells, clones that bound to those cells were excluded. CD326(EpCAM) Monoclonal Antibody (1B7) (eBioscience, 14-9326) was used as a positive control. Through the above experiments, we selected clones that provide antibodies that bind to more than 10 of the 12 types of cancer peritoneal disseminated cells, but do not bind to human EpCAM.
[0187] 2. Confirmation of antibody binding to human peripheral blood mononuclear cells. Furthermore, in order to select clones that provide antibodies that selectively bind to cancer peritoneal dissemination cells, clones that provide antibodies that bind to human peripheral blood mononuclear cells were excluded. Flow cytometry was used to measure the binding of human peripheral blood mononuclear cells to antibodies provided by each clone. Human Mononuclear Cells from Peripheral Blood (hMNC-PB), pooled, ultra-pure (PromoCell, C-12908) were used as the human peripheral blood-derived mononuclear cells. PE Goat Anti-Mouse Ig (Multiple Adsorption) (Becton, Dickinson and Company, 550589, hereafter "PE Goat Anti-Mouse Ig"), BV421 Mouse Anti-Human CD3 (Becton, Dickinson and Company, 562426), APC Mouse Anti-Human CD14 (Becton, Dickinson and Company, 555399), and BB515 Mouse Anti-Human CD19 (Becton, Dickinson and Company, 564456) were used for flow cytometry.
[0188] 3. Antibody purification from hybridoma supernatant Clones selected in steps 1 and 2 of Examples 1-3 were cultured in CD hybridoma medium (Thermo Fisher Scientific, 11279023). Antibodies were purified from the culture supernatant using MabSelectSuRe (GE Healthcare, 17-5438-02) (hereinafter referred to as "purified antibodies"). Antibody purification was performed according to conventional methods.
[0189] 4. Conjugation of purified antibodies to cultured human peritoneal mesothelial cells. To select antibodies that selectively bind to cancer peritoneal dissemination cells, antibodies that bind to cultured human peritoneal mesothelial cells were excluded from the purified antibodies obtained in step 3 of Example 1-3. Human Mesothelial Cells (Zenbio, MES-F, Lot. MESM012916B) (hereinafter referred to as "cultured human peritoneal mesothelial cells") were used as cultured human peritoneal mesothelial cells and were cultured in Mesothelial Cell Growth Medium (Zenbio, MSO-1). Flow cytometry was used to measure the binding of the purified antibodies to the cultured human peritoneal mesothelial cells. PE Goat Anti-Mouse Ig was used for the flow cytometry. Antibodies that did not bind to cultured human peritoneal mesothelial cells or showed weak binding were selected, and 14 types of purified antibodies were obtained (hereinafter referred to as "14 types of purified antibodies").
[0190] [Examples 1-4: Identification of candidate antigen molecules recognized by the acquired antibodies] Antigen candidate molecules were identified for 14 types of purified antibodies. As examples of identification methods, the methods for identifying antigen candidate molecules in 16B11, 16B12, and 21F7 are described in detail. In this experiment, 5D3, 9A1, and 21A3, which exhibited different binding patterns to cancer peritoneal dissemination cells compared to 16B11, were used as control antibodies. Cell lysates of NSC-15CF cells were prepared. To the cell lysates, 16B11, 16B12, 21F7, and one of three control antibodies (5D3, 9A1, 21A3) were added. Dynabeads Protein G (Life Technologies, 10003D) was then added, and the mixture was stirred and washed. Proteins bound to Dynabeads Protein G were digested using Tripsin / LysC (Promega, V5072) to obtain a peptide mixture. The solution containing the peptide mixture was subjected to LC-MS / MS analysis using UltiMate 3000 RSnano (Thermo Fisher Scientific) and Orbitrap Fusion (Thermo Fisher Scientific). The obtained LC-MS / MS data were subjected to comparative quantitative analysis and peptide / protein identification using Progenesis QI for Proteomics (Waters) and Mascot (Matrix Science) software to identify the binding proteins. The data for 16B11, 16B12, and 21F7 were compared with the data for the control antibody, and TSPAN8 was identified as a candidate antigen molecule for 16B11 and 21F7. In this experiment, a candidate antigen molecule for 16B12 could not be identified. Experiments were conducted on 5B7, 9F6, 12C12, 13A9, 15D1, 18C10, and 19E4 using the same method as described above, and TSPAN8 was identified as a candidate antigen molecule. In addition to 5D3, 9A1, and 21A3, 24C7 was used as a control antibody. Although 16B12 did not lead to the identification of a candidate antigen molecule, it showed a binding profile similar to that of 16B11 in Examples 1-3, so TSPAN8 was presumed to be a candidate antigen and further investigation was conducted. Furthermore, to identify the antigen, binding experiments were performed on human TSPAN8-Myc-DDK-expressing CHO-K1 cells. Human TSPAN8-Myc-DDK-expressing CHO-K1 cells were created by transfecting CHO-K1 cells with TSPAN8(Myc-DDK-tagged)-Human tetraspanin 8(TSPAN8) (ORIGENE, RC202694) (SEQ ID NO: 2). As a result, it was confirmed that 10 antibodies (also called "10 anti-TSPAN8 antibodies")—16B11, 16B12, 5B7, 9F6, 12C12, 13A9, 15D1, 18C10, 19E4, and 21F7—bound to human TSPAN8-Myc-DDK-expressing CHO-K1 cells and recognized TSPAN8 as an antigen.
[0191] [Examples 1-5: Confirmation of the binding activity of anti-TSPAN8 antibodies to various cells] 1. Confirmation and quantification of binding activity to cancer peritoneal dissemination cells. The binding of seven types of cancer peritoneal dissemination cells (KM-291-As, KM-555-As, KM-556-As, P-249-As, KM-568-As, KM-570-As, and KM-577-As), isolated from ascites fluid of gastric cancer patients, to four types of anti-TSPAN8 antibodies was measured by flow cytometry. KM-291-As was prepared from patient ascites fluid using the same method as in Example 1-1. Since the prepared KM-291-As contained a large number of hematopoietic cells expressing CD45, CD45-expressing cells were removed using a column to concentrate cancer cells. Specifically, 5 × 10⁻⁶ cells were removed. 7 A cell suspension containing 5 × 10 cells was passed through CD45 MicroBeads, human (Miltenyi Biotec, 130-045-801) using a standard method with Pre-Separation Columns (30 μm) (Miltenyi Biotec, 130-041-407) and Separation Columns (Miltenyi Biotec, 130-042-401) (hereinafter referred to as "Column"). The filtration through the Column was collected in a 50 mL centrifuge tube and centrifuged. 10 mL of buffer was added to the precipitate and the cells were resuspended. From this cell suspension, 5 × 10 cells were extracted. 6Cells were separated into 1.5 mL microcentrifuge tubes (WATSON, 131-7155C) and precipitated by centrifugation. A cell suspension was prepared by adding 950 μL of PBS (FCM buffer) containing 2% FBS and 100 μg / mL Penicillin-Streptomycin (Thermo Fisher Scientific, 15140-122) to the precipitate. 50 μL of FcR Blocking Reagent was added and the mixture was reacted on ice for 10 minutes. 100 μL of this reaction solution was dispensed into seven 1.5 mL microcentrifuge tubes, and the cells were stained using the following method. 5 μL of mouse IgG1-PE antibody (Miltenyi Biotec, 130-092-212) was added to three of the seven microcentrifuge tubes, and then 2.5 μL of Alexa Fluor647-labeled control antibody was added to each microcentrifuge tube to create an isotype control. As control antibodies, one of the following was used: mouse IgG2a Isotype control (Becton, Dickinson and Company, 558053), mouse IgG2b Isotype control (Becton, Dickinson and Company, 558713), or mouse IgG3 Isotype control (Becton, Dickinson and Company, 560803). 5 μL of CD326 (EpCAM)-PE (Miltenyi Biotec, 130-091-253) was added to the remaining four microtubes. Then, 2.5 μL (0.25 μg / tube) of 16B11, 16B12, 9F6, and 18C10 were added to each tube to stain the cells, creating four evaluation antibody samples. Each microtube was incubated on ice for 30 minutes after antibody addition. Add 1 mL of FCM buffer and centrifuge. Then, add 500 μL of FCM buffer to the resulting precipitate and resuspend the cells.5 μL of 7-AAD (Becton, Dickinson and Company, 559925) was added, and the entire volume was transferred to a 5 mL round-bottom polystyrene tube with a cell strainer cap (CORNING, 352235). Measurement was performed using a FACSerse flow cytometer (Becton, Dickinson and Company). BD FACSuite software (Becton, Dickinson and Company) was used for data acquisition. The preparation of KM-555-As, KM-556-As, P-249-As, KM-568-As, KM-570-As, and KM-577-As was carried out in the same manner as the preparation of KM-291-As. For binding measurements with KM-555-As and KM-556-As, 16B11, 9F6, and 18C10 were used as evaluation antibody samples. For binding measurements with P-249-As, 16B11 and the commercially available anti-TSPAN8 antibody TSPAN8 Antibody, anti-human, REAfinity (130-106-855, Miltenyi, hereafter referred to as "REA443") were used as evaluation antibody samples. For binding measurements with KM-568-As, KM-570-As, and KM-577-As, 16B11, 9F6, 18C10, and REA443 were used as evaluation antibody samples. In all experiments, Isotype Control Antibody, mouse IgG1 (130-113-196, Miltenyi) was used as the isotype control. For cell staining, IgG2a-VioBlue antibody (Miltenyi Biotec, 130-113-277) and CD326(EpCAM)-VioBlue antibody (Miltenyi Biotec, 131-113-266) were used. The flow cytometry results of each cancer peritoneal dissemination cell were analyzed using BD FACSuite software. Specifically, the data were plotted as FSC-A(lin) / SSC-A(log), the resulting cell populations were gated, and then expanded again as FSC-W(lin) / FSC-A(lin). Only the singlet populations were gated to create subsets for analysis. For the analysis of KM-291-As cells, the subset was expanded as PE(log) / Alexa Fluor647(log). For the analysis of KM-555-As, KM-556-As, P-249-As, KM-568-As, KM-570-As, and KM-577-As cells, data expanded as VioBlue(log) / Alexa Fluor647(log) was used. 1 × 10⁻⁶ data were obtained for each sample. 4 Data was obtained for a subset of cells. The obtained fcs files were analyzed using FlowJo (Becton, Dickinson and Company) to create histograms for Alexa Fluor647. For each isotype and evaluation antibody, the MFI of the positive population of Alexa Fluor647 was calculated, and the ΔMFI was calculated by subtracting the MFI of each isotype from the MFI of each antibody (Table 1). As examples of the obtained histograms, Figures 1-1 to 1-3 show histograms illustrating the binding of 16B11 and 16B12 in binding measurements with KM-291-As, and the binding of 16B11, 9F6, and 18C10 in binding measurements with KM-555-As and KM-556-As, respectively.
[0192] 2. Confirmation and quantification of binding activity to cultured human peritoneal mesothelial cells. The binding activity of the 10 anti-TSPAN8 antibodies identified in Examples 1-4 to cultured human peritoneal mesothelial cells was measured. The cultured human peritoneal mesothelial cells were normal cells. The binding of 10 types of anti-TSPAN8 antibodies obtained in Examples 1-3, as well as a commercially available anti-TSPAN8 antibody, Purified anti-human TSPAN8 Antibody (BioLegend, 363702 Clone TAL69, hereinafter referred to as "TAL69"), to cultured human peritoneal mesothelial cells was measured by flow cytometry. PE Goat Anti-Mouse Ig was used as the secondary antibody. The resulting histograms are shown in Figures 2-1 and 2-2. Furthermore, the MFI for each cell population was calculated by analyzing the flow cytometry results using FlowJo. Three antibodies were used as negative control antibodies: Ultra-LEAF Purified Mouse IgG1,κ Isotype Ctrl Antibody (BioLegend, 401408), Purified NA / LE Mouse IgG2a,κ Isotype Control (Becton, Dickinson and Company, 554645), and Purified NA / LE Mouse IgG2b,κ Isotype Control (Becton, Dickinson and Company, 559530). The ΔMFI values for 16B11, 16B12, 9F6, 18C10, and TAL69 are listed in Table 1. The ΔMFI value of each antibody was calculated by subtracting the MFI value of the negative control antibody from the MFI value of each antibody.
[0193] 3. Confirmation and quantification of binding activity to peritoneal mesothelial cells derived from gastric cancer peritoneal dissemination patients. Peritoneal mesothelial cells (referred to herein as "patient-derived peritoneal mesothelial cells") KM-501-As and KM-503-As, isolated from the ascites fluid of human gastric cancer peritoneal dissemination patients, were obtained by the following method. During the cell establishment process in Example 1-1, mesothelial cells proliferated in a cobblestone-like pattern across the entire surface of the dish were observed. These mesothelial cells were harvested using 0.05% trypsin-EDTA and resuspended in 10 mL of D-MEM (high glucose) (Fujifilm Wako Pure Chemical Industries, 044-29765) containing 10% FBS and ×1 Antibiotic-Antimycotic. 4 × 10 5Each cell was divided into a 1.5 mL microcentrifuge tube, the supernatant was removed after centrifugation, and the cells were suspended in 96 μL of FCM buffer. 4 μL of FcR Blocking Reagent was added and the mixture was allowed to react on ice for 10 minutes. 50 μL of this reaction mixture was dispensed into another 1.5 mL microcentrifuge tube, and 2 × 10 cells were added. 5 Two 50 μL microcentrifuge tubes were used. 2 μL of CD45-APC antibody (Miltenyi Biotec, 130-091-230) and 0.5 μL of CD326 (EpCAM)-PE (Miltenyi Biotec, 130-113-264) were added to one tube. 2 μL of mouse IgG2a-APC antibody (Miltenyi Biotec, 130-091-836) and 0.5 μL of mouse IgG1-PE antibody were added to the other tube. Each tube was incubated on ice for 30 minutes. 1 mL of FCM buffer was added to each tube, and the supernatant was removed by centrifugation. 500 μL of FCM buffer was added to the precipitate to resuspend the cells, and analysis was performed using FACSVerse. The cell population was gated using FSC-A(lin) and SSC-A(log), and the subset was further expanded using PE(log) and APC(log) to obtain data. The obtained fcs files were analyzed with FlowJo. As a result, it was confirmed that this cell population consisted of normal cells that were CD45-negative and EpCAM-negative. These patient-derived peritoneal mesothelial cells are thought to be normal cells derived from the omentum and mesenteric peritoneum, which serve as scaffolds for cancer cells to engraft and proliferate during peritoneal dissemination. KM-501-As and KM-503-As of the isolated patient-derived peritoneal mesothelial cells were used in the following experiments. The binding of ten anti-TSPAN8 antibodies and TAL69 to KM-501-As and KM-503-As was performed using the same method as the binding measurement to cultured human peritoneal mesothelial cells described in Example 1-5, Section 2. Histograms of 16B11, 16B12, 9F6, 18C10, and TAL69 to KM-501-As and KM-503-As are shown in Figures 3-1 and 3-2, and the ΔMFI values are shown in Table 1.
[0194] 4. Confirmation and quantification of binding activity to cultured human umbilical cord vascular endothelial cells. The binding of 10 anti-TSPAN8 antibodies and TAL69 to cultured human umbilical cord endothelial cells was measured by flow cytometry. Cultured human umbilical cord endothelial cells (PromoCell, C-12200) were cultured using the Endothelial Cell Growth Medium 2 Kit (PromoCell, C-22111). As negative control antibodies, Ultra-LEAF Purified Mouse IgG1,κ Isotype Ctrl Antibody, Purified NA / LE Mouse IgG2a,κ Isotype Control, Ultra-LEAF Purified Mouse IgG2b,κ Isotype Ctrl Antibody (BioLegend, 400348), and LEAF Purified Mouse IgG3,κ Isotype Ctrl Antibody (BioLegend, 401310) were used. PE Goat Anti-Mouse Ig was used as the secondary antibody. Histograms of binding between 10 anti-TSPAN8 antibodies and TAL69 are shown in Figure 4. The ΔMFI values for 16B11, 16B12, 9F6, 18C10, and TAL69 are listed in Table 1. The ΔMFI value was calculated by subtracting the MFI of the negative control antibody from the MFI of each antibody. The histogram results in Figures 1 to 4 and the results in Table 1 show that 16B11 and 16B12 show high binding to cancer peritoneal dissemination cells, but low binding to normal cells (cultured human peritoneal mesothelial cells, patient-derived peritoneal mesothelial cells, and cultured human umbilical cord vascular endothelial cells). On the other hand, other anti-TSPAN8 antibodies such as 9F6, 18C10, and commercially available anti-TSPAN8 antibodies (TAL69 or REA443) showed lower binding to cancer peritoneal dissemination cells than 16B11 and 16B12, but higher binding to normal cells than 16B11 and 16B12. From these results, it became clear that 16B11 and 16B12 have significantly different properties from other anti-TSPAN8 antibodies (9F6, 18C10, TAL69, etc.). [Table 1]
[0195] [Example 2: Sequence determination of 16B11 and 16B12] Following conventional methods, the genes coding the heavy and light chains of 16B11 and 16B12 were cloned, and the antibodies were sequenced. Verosimune technology is a technique for producing antibodies using transgenic mice in which the variable regions of the endogenous immunoglobulin heavy and light chains are replaced with corresponding human variable regions. Therefore, the antibodies obtained using verosimune technology are antibodies (also referred to as "chimeric antibodies" in this specification) that have the variable region of a human antibody and the constant region of a mouse antibody. The amino acid sequence of the obtained heavy chain variable region of 16B11 is shown in SEQ ID NO: 34, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 36. The amino acid sequence of the obtained heavy chain variable region of 16B12 is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 37.
[0196] [Example 3: Preparation of complete anti-TSPAN8 antibody] [Example 3-1: Preparation of an expression vector used for producing a complete anti-TSPAN8 antibody] Fully human antibodies of 16B11 and 16B12 were prepared by concatenating the amino acid sequences of the human variable region and the human constant region identified in Example 2. Polypeptides were designed by ligating the amino acid sequence encoding the signal sequence described in SEQ ID NO: 38 to the N-terminus of the heavy chain variable regions of 16B11 and 16B12, and the amino acid sequence of the constant region of hi-IgG1 (amino acid sequences 122 to 451 of SEQ ID NO: 4 or 10) to the C-terminus. Furthermore, a mutation was introduced in which the 16th arginine (R) was replaced with glycine (G) in the furin cleavage sequence consisting of amino acid sequences 16 to 19 of the heavy chain variable region of the said polypeptide (J. Biol. Chem., 1992, Vol. 267, p. 16396-16402). The polynucleotides encoding the designed polypeptides were introduced into pcDNA3.4 TOPO® vectors (Thermo Fisher Scientific). The resulting heavy chain vectors are referred to as pcDNA3.4-16B11.1_HC and pcDNA3.4-16B12.1_HC, respectively. Furthermore, polypeptides were designed by ligating the amino acid sequence encoding the signal sequence described in SEQ ID NO: 39 to the N-terminus of the light chain variable region of 16B11, and the amino acid sequence encoding the signal sequence described in SEQ ID NO: 40 to the N-terminus of the light chain variable region of 16B12, and ligating the constant region amino acid sequence of the hi-κ chain (amino acid sequences 108 to 213 of SEQ ID NO: 8 or 12) to the C-terminus of both antibodies. The polynucleotides encoding the designed polypeptides were introduced into pcDNA3.4 TOPO® vectors. The resulting light chain vectors are referred to as pcDNA3.4-16B11_LC and pcDNA3.4-16B12_LC, respectively.
[0197] [Example 3-2: Preparation of complete anti-TSPAN8 antibody] Antibodies for 16B11.1 were prepared using pcDNA3.4-16B11.1_HC and pcDNA3.4-16B11_LC. More specifically, ExpiCHOExpression Medium (Thermo Fisher Scientific, A2910001) is approximately 6.0 × 10⁻⁶ 6ExpiCHO-S cells (Thermo Fisher Scientific, A29127), cultured to a concentration of pcDNA3.4-16B11.1_HC and pcDNA3.4-16B11_LC, were transfected using the gene transfection reagent ExpiFectamineCHO Transfection Kit (Thermo Fisher Scientific, A29129) and cultured for 12 days. The culture supernatant was purified using MabSelectSuRe to obtain purified complete hematopoietic antibodies. The obtained antibodies are referred to as 16B11.1. The nucleotide sequence of the heavy chain of 16B11.1 is shown in SEQ ID NO: 3, the amino acid sequence encoded therein is shown in SEQ ID NO: 4, the nucleotide sequence of the light chain of the antibody is shown in SEQ ID NO: 7, and the amino acid sequence encoded therein is shown in SEQ ID NO: 8. 16B12.1 can be prepared using pcDNA3.4-16B12.1_HC and pcDNA3.4-16B12_LC by the same method as described above. The nucleotide sequence of the heavy chain of 16B12.1 is shown in SEQ ID NO: 9, the amino acid sequence encoded therefrom is shown in SEQ ID NO: 10, the nucleotide sequence of the light chain of the antibody is shown in SEQ ID NO: 11, and the amino acid sequence encoded therefrom is shown in SEQ ID NO: 12.
[0198] [Example 4: Identification of the epitope site on the antigen side to which the antibody binds] [Example 4-1: Epitope mapping by hydrogen-deuterium exchange mass spectrometry] To identify the epitope of 16B11.1, hydrogen-deuterium exchange mass spectrometry (HDX-MS) was performed. As a result, the human TSPAN8 region corresponding to amino acid numbers 126-155 of SEQ ID NO: 2 was detected as a region where the degree of deuterium exchange decreased in the presence of 16B11.1. From this result, it was estimated that the human TSPAN8 region corresponding to amino acid numbers 126-155 of SEQ ID NO: 2 is the epitope of 16B11.1.
[0199] [Example 4-2: Narrowing down important epitopes by introducing human TSPAN8 mutations] To confirm whether the region estimated in Example 4-1 is the 16B11.1 epitope, chimeric proteins were created in which the region was replaced with a homologous region of mouse or rat TSPAN8, and binding was evaluated. Amino acid numbers 126-155 of mouse TSPAN8, corresponding to amino acid numbers 126-155 of human TSPAN8, are shown in SEQ ID NO: 41, and amino acid numbers 126-155 of rat TSPAN8 are shown in SEQ ID NO: 42. To create cells expressing a TSPAN8-GFP fusion protein, the human TSPAN8 sequence was excised from TSPAN8(Myc-DDK-tagged)-Human tetraspanin 8(TSPAN8) (ORIGENE, RC202694) used in Examples 1-4 using restriction enzymes. The excised human TSPAN8 sequence was subcloned into a pCMV6-AC-GFP vector (ORIGENE, PS100010) (hereinafter referred to as the "human TSPAN8-GFP expression vector"). Furthermore, using the In-Fusion® HD Cloning Kit (Takara Bio, 639633), a vector was prepared in which the sequences corresponding to amino acid numbers 126-155 of the human TSPAN8-GFP expression vector described in Sequence ID No. 2 were replaced with sequences corresponding to amino acid numbers 126-155 of mouse or rat TSPAN8. The prepared vectors were introduced into CHO-K1 cells to create cells that transiently expressed human TSPAN8-GFP protein, human mouse TSPAN8-GFP chimeric protein, or human rat TSPAN8-GFP chimeric protein. These cells were referred to as wild-type human TSPAN8-expressing CHO-K1 cells, human mouse TSPAN8 chimeric protein-expressing CHO-K1 cells, or human rat TSPAN8 chimeric protein-expressing CHO-K1 cells, respectively. Cells into which the pCMV6-AC-GFP vector was introduced (referred to as mock cells) were also created. The binding of 16B11, 16B12, and TAL69 to GFP-positive cells in these cells was measured by flow cytometry. No decrease in TAL69 binding was observed in human rat or human mouse TSPAN8 chimeric protein-expressing CHO-K1 cells. 16B11 and 16B12 showed binding to human rat TSPAN8 chimeric protein-expressing CHO-K1 cells at a similar level to wild-type human TSPAN8-expressing CHO-K1 cells. On the other hand, reduced binding was observed to human mouse TSPAN8 chimeric protein-expressing CHO-K1 cells compared to wild-type human TSPAN8-expressing CHO-K1 cells (Figure 5-1). To identify the amino acid sequence contributing to the attenuation of binding activity to human mouse TSPAN8 chimeric protein-expressing CHO-K1 cells, we compared the sequences of human, mouse, rat, and cynomolgus monkey TSPAN8 proteins with those corresponding to amino acid sequences 126-155 of human TSPAN8 (Figure 5-2). Sequence IDs 41, 42, and 43 represent the sequences corresponding to amino acid sequences 126-155 of mouse, rat, and cynomolgus monkey TSPAN8, respectively. As a result, only the 131st amino acid was different in the mouse TSPAN8 protein. Based on this information, it was inferred that the 131st threonine (T) of the human TSPAN8 protein described in Sequence ID 2 is important for binding to 16B11 or 16B12. Furthermore, to determine whether the 131st amino acid of human TSPAN8 contributes to the binding of 16B11 or 16B12, a substitution of this amino acid was created. Specifically, vectors containing the base sequence encoding human TSPAN8-GFP fusion proteins (referred to as "human TSPAN8(T131A)-GFP" or "human TSPAN8(T131N)-GFP," respectively) were created by substituting the 131st threonine (T) of the human TSPAN8 amino acid sequence in SEQ ID NO: 2 with alanine (A) or asparagine (N). These vectors were then introduced into CHO-K1 cells to construct cells transiently expressing human TSPAN8(T131A)-GFP and human TSPAN8(T131N)-GFP. The constructed cells are referred to as human TSPAN8(T131A)-expressing CHO-K1 cells or human TSPAN8(T131N) cells. The binding of 16B11, 16B12, and TAL69 to GFP-positive cells in these cells was measured by flow cytometry (Figure 5-3). The results showed that the binding of 16B11 and 16B12 to human TSPAN8(T131A)-expressing CHO-K1 cells and human TSPAN8(T131N)-expressing CHO-K1 cells was attenuated compared to binding to wild-type human TSPAN8-expressing CHO-K1 cells. On the other hand, TAL69 showed comparable binding activity to both cell types. As a result, it was found that in the human TSPAN8 region corresponding to amino acid numbers 126-155 of the epitope-identified sequence number 2, threonine at position 131 is an essential amino acid for binding to 16B11 and 16B12. Table 2-1 shows the ΔMFI values calculated by subtracting the MFI for binding to mock cells from the MFI for binding to each TSPAN8-expressing cell. Table 2-2 shows the relative ΔMFI values for binding to human mouse TSPAN8 chimeric protein-expressing CHO-K1 cells, human rat TSPAN8 chimeric protein-expressing CHO-K1 cells, and human TSPAN8 (T131A or T131N)-expressing CHO-K1 cells, with the ΔMFI for binding to wild-type human TSPAN8-expressing CHO-K1 cells set to 100. [Table 2-1] [Table 2-2]
[0200] [Example 4-3: Binding competition experiment] We investigated whether 16B11 or 16B12 competes with other anti-TSPAN8 antibodies (9F6, 18C10, or TAL69) for binding to TSPAN8. To investigate the competition between 16B11 and other anti-TSPAN8 antibodies (9F6, 18C10, or TAL69), changes in the amount of 16B11 bound to NSC-15CF cells were measured by flow cytometry (Experiment 1; Figure 6-1). Specifically, 2 × 10⁻⁶ 5 To each NSC-15CF sample, Alexa Fluor647-labeled 16B11 at a final concentration of 1 μg / mL and another anti-TSPAN8 antibody (one of 16B11, 9F6, 18C10, or TAL69) were added to a final concentration of 100 μg / mL. The amount of 16B11 bound to NSC-15CF was measured using a flow cytometer. Ultra-LEAF Purified Mouse IgG1,κ Isotype Ctrl Antibody, Ultra-LEAF Purified Mouse IgG2a,κ Isotype Ctrl Antibody (BioLegend, 400264), and Ultra-LEAF Purified Mouse IgG2b,κ Isotype Ctrl Antibody were used as negative control antibodies. The results showed that 16B11 binding was attenuated only when 16B11 itself was added. To investigate the competition between 16B12 and other anti-TSPAN8 antibodies (16B11, 9F6, 18C10, or TAL69), the change in the binding amount of 16B11, 9F6, or 18C10 to NSC-15CF by 16B12 was measured by flow cytometry (Experiment 2; Figure 6-2). Specifically, 1 × 10⁻⁶ 5To NSC-15CF cells, Alexa Fluor647-labeled 16B11, 9F6, or 18C10 at a final concentration of 0.25 μg / mL and 16B12 at a final concentration of 100 μg / mL were added, and the amount of 16B11, 9F6, or 18C10 bound to NSC-15CF was measured using a flow cytometer. LEAF Purified Mouse IgG3,κ Isotype Ctrl Antibody was used as the negative control antibody. As a result, the binding of 16B11 was attenuated by 16B12. The binding of other antibodies was not affected. Similarly, competitive experiments were conducted using Alexa Fluor647-labeled 16B12 and other anti-TSPAN8 antibodies (16B11, 16B12, 9F6, 18C10, or TAL69) (Experiment 3; Figure 6-3). LEAF Purified Mouse IgG3,κ Isotype Ctrl Antibody, Ultra-LEAF Purified Mouse IgG2a,κ Isotype Ctrl Antibody, Ultra-LEAF Purified Mouse IgG2b,κ Isotype Ctrl Antibody, and Ultra-LEAF Purified Mouse IgG1,κ Isotype Ctrl Antibody were used as negative control antibodies. The results showed that 16B12 binding was attenuated only when 16B11 or 16B12 itself was added. Since the binding of 16B11 and 16B12 competes with each other, it was inferred that 16B11 and 16B12 recognize similar epitopes. Table 3 shows the relative values when the competing antibody was added, with the value when the Isotype Control was added set to 100, calculated by subtracting the MFI of unstained cells from the MFI of each labeled antibody-bound antibody. [Table 3]
[0201] [Example 5: Production of 60As6-Luc / GFP cells] 60As6-Luc / GFP cells, which express luciferase protein and green fluorescent protein (GFP) in 60As6 cells derived from ascites fluid of gastric cancer patients, were prepared using the following method. [Example 5-1: Preparation of a virus solution containing Luc / GFP] Lentiviruses were generated using L293T cells (Thermo Fisher Scientific, K4975-00) according to a standard procedure. Lentiviruses were prepared using MISSION® Lentiviral Packaging Mix (SIGMA, SHP001) and a modified pCDH-CMV-GL3-EF1a-GFP-T2A-puro vector (donated by Associate Professor Ryo Takahashi of the Department of Cell and Molecular Biology, Graduate School of Biomedical Sciences, Hiroshima University (PLoS One, 2015, Vol.10, e0123407, Front Biosci., 2008, Vol.13, pp.1619-1633)). The virus was filtered from the culture supernatant of virus-containing cells using a 45 μm Millex®-HV filter (Merck Millipore, SLHV033RS) to obtain a virus solution, which was then frozen and stored at -80°C. [Example 5-2: Virus infection of 60As6 cells] Virus infection of 60As6 cells (donated by Dr. Gokichi Yanagihara, National Cancer Center) was performed according to standard procedures. RPMI-1640 containing 10% FBS was used as the culture medium. Three days after infection, the culture medium was removed from the 60As6 cell plate and replaced with RPMI-1640 (selection medium) containing 10% FBS and 2 μg / mL Puromaycin (Thermo Fisher Scientific, A-11138-02), and cultivation was continued. Subsequently, uninfected cells were removed by repeating culture and subculturing in selection medium, and it was confirmed that the virus had been completely removed. The established cells were referred to as 60As6-Luc / GFP cells. These cells expressed luciferase and GFP. Furthermore, it was confirmed by flow cytometry that 60As6-Luc / GFP cells endogenously expressed high levels of TSPAN8.
[0202] [Example 6: Evaluation of ADCC activity of 16B11.1, a fully human antibody] ADCC activity induced by the fully human anti-TSPAN8 antibody 16B11.1 was measured. ADCC activity can be measured by evaluating the effector cell's ability to damage target cells. In this example, under co-culture conditions of effector cells (NK cells) and target cells (60As6-Luc / GFP cells), NK cells were activated by 16B11.1, and the resulting cytotoxic activity of 60As6-Luc / GFP cells being damaged by ADCC activity was measured using luciferase as an indicator. NK cells were isolated from frozen human PBMCs (ePBMC®, Characterized Cryopreserved Human PBMC, Cellular Technology Limited, CTL-CP1) using an NK cell isolation kit (NK Cell Isolation Kit, human, Miltenyi Biotec, 130-092-657) and cultured in NK cell medium (NK MACS Medium, Miltenyi Biotec, 130-114-429). 5 × 10⁶ 60As6-Luc / GFP cells suspended in RPMI-1640 (SIGMA, R8758-500mL) medium containing 5% FBS (Hyclone, SH30084.03) were placed in a round-bottom 96-well plate (Sumitomo Bakelite, MS-9096U). 3 cells / 25μL / well, 5×10 NK cells 4 Cells were seeded at 50 μL / well. Furthermore, 25 μL / well of a solution of 16B11.1 or our proprietary anti-KLH antibody (3G6) as a negative control antibody, diluted to final concentrations of 1, 10, 100, 1000, and 10000 ng / mL, was added. Luciferase luminescence after 24 hours was measured using a luciferase quantification kit (ONE-GloLuciferase Assay System, Promega, E6120). Since luciferase luminescence indicates the viability of 60As6-Luc / GFP cells, a decrease in luciferase luminescence can be used to measure cytotoxic activity mediated by ADCC activity. The vertical axis in Figure 7 represents the relative luciferase luminescence of each sample, with the luciferase luminescence of the culture medium alone set to 100% and the luciferase luminescence of 60As6-Luc / GFP cells without antibody added to 0%. The horizontal axis shows the concentration of the antibody added to each well. As shown in Figure 7, target cells were damaged by ADCC activity only when 16B11.1 was added.
[0203] [Example 7: Preparation of anti-TSPAN8-anti-CD3 bispecific antibody] [Example 7-1: Preparation of a bispecific antibody vector for anti-TSPAN8 antibody] We introduced LALA mutations (L234A and L235A) in which amino acids 238 and 239 (EU index: 234 and 235) of the heavy chain of 16B11.1 were replaced with alanine (A) from leucine (L), respectively; Knobs into holes mutations in which amino acids 370, 372 and 411 (EU index: 366, 368 and 407) were replaced with serine (S), L with A, and tyrosine (Y) with valine (V), respectively; and a mutation in which amino acid 301 (EU index: 297) was replaced with glycine (G) from asparagine (N). The designed heavy chain amino acid sequence of 16B11.1 is shown in Sequence ID No. 6. The constructed vector is referred to as pcDNA3.4-16B11.1_HC_H.
[0204] [Example 7-2: Bispecific antibody vector preparation using anti-human CD3 antibody] The sequence design of the humanized anti-CD3 antibody was performed according to the method described in the literature (Front Biosci., 2008, Vol.13, pp.1619-1633), based on the heavy chain variable region and light chain variable region sequences of the mouse anti-CD3 antibody described in Japanese Patent No. 5686953. Back mutations were introduced during this process. The position of the back mutations within the framework region was determined by analyzing the three-dimensional structural information (PDB Code: 5FCS) using the integrated computational chemistry system MOE provided by MOLSIS Inc. The humanized anti-CD3 antibody was designed so that the heavy chain variable region (SEQ ID NO: 14, amino acids 1 to 125), linker (SEQ ID NO: 14, amino acids 126 to 145), light chain variable region (SEQ ID NO: 14, amino acids 146 to 254), hinge (SEQ ID NO: 14, amino acids 255 to 269), CH2 domain (SEQ ID NO: 14, amino acids 270 to 379), and CH3 domain (SEQ ID NO: 14, amino acids 380 to 486) are arranged in that order. Furthermore, Sequence ID No. 14 incorporates the following mutations: (1) substitution of amino acids 44 and 247 with cysteine (C), (2) substitution of amino acid 259 (EU index: 220) from C to S, (3) LALA mutations that substitute L for amino acids 273 and 274 (EU index: 234 and 235), (4) Knobs into holes mutations that substitute T for tryptophan (W) at amino acid 405 (EU index: 366), and (5) a mutation that substitutes N for G at amino acid 336 (EU index: 297). To introduce these mutations, polynucleotides encoding amino acid sequences containing each mutation site were synthesized and inserted into a pcDNA3.1(+) vector (Thermo Fisher Scientific, V79020). The resulting vector is referred to as pcDNA3.1-m7_scFV_K. The base sequence of the humanized anti-CD3 antibody produced is shown in SEQ ID NO: 13, and the amino acid sequence is shown in SEQ ID NO: 14.
[0205] [Example 7-3: Preparation of anti-TSPAN8-anti-CD3 bispecific antibody] To produce bispecific antibodies composed of the Fab region of an anti-TSPAN8 antibody and the scFv and Fc regions of an anti-CD3 antibody, pcDNA3.4-16B11.1_HC_H, pcDNA3.4-16B11_LC, and pcDNA3.1-m7_scFV_K were transfected into ExpiCHO-S® cells in the same manner as in Example 3. The culture supernatant was then analyzed using MabSelect The antibody was purified using SuRe, and then further purified using a gel filtration column HiLoad26 / 600 Superdex® 200pg (GE Healthcare, 28-9893-36) to obtain a purified antibody with a purity of over 95%. The obtained antibody is referred to as an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody.
[0206] [Example 8: Evaluation of binding activity of anti-TSPAN8-anti-CD3 bispecific antibody] The binding activity of anti-TSPAN8(16B11)-anti-CD3 bispecific antibodies to TSPAN8 and CD3 was evaluated by ELISA using either the TSPAN8 LEL protein or the CD3εδ complex protein. Specifically, 1 μg / mL of TSPAN8 Protein, Human, Recombinant (SinoBiological, 15683-H07H) or Human CellExp CD3 epsilon & CD3 delta Heterodimer, Human Recombinant (BioVision, P1183-10), diluted in PBS, was added to 30 μL / well of 384-well White Plates, MaxiSorp (Nunc, 460372). After standing overnight at 4°C, the supernatant was removed, and 120 μL / well of Blocking One (Nacalai Tesque, 03953-95) was added. After standing at room temperature for 1 hour, the supernatant was removed, and the mixture was washed twice with TBST buffer (Thermo Fisher Scientific, 28360). Then, 30 μL / well of anti-TSPAN8 (16B11)-anti-CD3 bispecific antibody diluted with 10% Blocking One-containing TBST was added, and the mixture was left to stand at room temperature for 1 hour. The antibody solution was removed, and the mixture was washed twice with TBST buffer. Then, 30 μL / well of Goat Anti-Human Kappa, Mouse ads-HRP (Southern Biotech, 2061-05), diluted 5000-fold with 10% Blocking One-containing TBST, was added, and the mixture was left to stand at room temperature for 30 minutes. The antibody solution was removed, and the mixture was washed four times with TBST buffer. Then, 30 μL / well of BM Chemiluminescence ELISA Substrate (POD) (Roche, 11582950001) was added. After reacting at room temperature for 15 minutes, chemiluminescence was measured using ARVO X3 (Perkin Elmer). As a result, the EC50 values for TSPAN8 and CD3 were calculated to be 1.0 μg / mL (8.1 nM) and 4.6 μg / mL (36 nM), respectively (Figure 8).
[0207] [Example 9: Evaluation of RTCC activity of anti-TSPAN8-anti-CD3 bispecific antibody] RPMI-1640 (Thermo Fisher Scientific, 11875-119) 500 mL, FBS 50 mL, MEM Non-essential Amino Acid (Merck, M7145) 5 mL, Sodium pyruvate (Merck, S8636) 5 mL, GlutaMAX A culture medium was prepared by adding 5 mL of I (Thermo Fisher Scientific, 35050-061), 5 mL of penicillin streptomycin (Thermo Fisher Scientific, 15070-063), and 5 mL of HEPES (Thermo Fisher Scientific, 15630-080) (hereinafter referred to as "culture medium" in this example). 2 × 10⁶ cells of the 60As6-Luc / GFP cells prepared in Example 4 were cultured in the medium. 5 Cell suspensions prepared at a concentration of cells / mL were seeded in 50 μL portions into flat-bottom 96-well plates (IWAKI, 3860-096) and cultured at 37°C in a 5% CO2 incubator. After 3 hours, 1 × 10⁶ cells were cultured in culture medium. 6 Frozen human peripheral blood mononuclear cells (LP.CR.MNC 10M; AllCells LLC, 4W-270), prepared at a concentration of 100 μL / mL, were seeded in 100 μL portions of 96-well plates during culture. 50 μL of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody, prepared to final concentrations of 0, 3, 10, 30, 100, 300, 1000, 3000, and 10000 ng / mL, was added to each well. The fluorescence (GFP) area of each well was measured after 3 days using an IncuCyte® ZOOM (Sartorius) under 37°C and 5% CO2 culture conditions. The fluorescence area was used as an indicator of cell proliferation, and the cell proliferation curve is shown in Figure 9. The vertical axis of Figure 9 shows the relative fluorescence area of 60As6-Luc / GFP cells, with the fluorescence area of wells containing only culture medium set to 0% and the fluorescence area of wells without antibody solution set to 100%. As a result, the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody showed an inhibitory effect on cell proliferation in vitro against TSPAN8-expressing gastric cancer cells, specifically 60As6-Luc / GFP cells.
[0208] [Example 10: Evaluation of the efficacy of anti-TSPAN8-anti-CD3 bispecific antibody using patient ascites cells] When anti-TSPAN8-anti-CD3 bispecific antibodies bind to cancer cells and immune cells contained in patient ascites fluid, the immune cells are activated and the cancer cells are damaged. The cancer cell toxicity and immune cell activation effects of anti-TSPAN8(16B11)-anti-CD3 bispecific antibodies were evaluated using the following method. Patient ascites cells were obtained by performing hemolysis on patient ascites fluid as in Example 1-1, and then using cells that had been cryopreserved. The thawed cells were cultured in the same medium as in Example 9 at a rate of 2 × 10⁶. 6Cells were prepared to a concentration of 100 μL / mL, and the cell solution was seeded into flat-bottom 96-well plates at a rate of 100 μL / well. The test antibody used was an anti-TSPAN8 (16B11)-anti-CD3 bispecific antibody and a control antibody (a bispecific antibody consisting of an anti-KLH antibody and an anti-CD3 antibody, with the Fab of 16B11.1 replaced by the Fab of an anti-KLH (keyhole limpet hemocyanin) antibody). The test antibody was diluted from 10 μg / mL to 0.1 ng / mL at a 10-fold common ratio. After adding the test antibody to the 96-well plate containing the seeded cells, the cells were cultured at 37°C in a 5% CO2 incubator. Culture medium was used for cultivation. After 3 days, the cells were harvested and seeded into V-bottom microplates. Cells adhering to the plate at harvesting were detached with Accutase (Innovative Cell Technologies, AT-104) and then added to the V-bottom microplates. After centrifugation at 720×g for 2 minutes, the supernatant was removed, and 20 μL / well of a solution was added to a staining buffer (PBS containing 10% FBS, 0.09% NaN32mM EDTA) with 1 / 40th the volume of Human BD Fc Block (Becton, Dickinson and Company, 564220). To each well, 10 μL / well of FITC Mouse Anti-Human CD4 (Becton, Dickinson and Company, 550628), APC-H7 Mouse anti-Human CD8 (Becton, Dickinson and Company, 560179), APC Mouse Anti-Human CD45 (Becton, Dickinson and Company, 555485), PE Mouse Anti-Human CD25 (Becton, Dickinson and Company, 555432), and Brilliant Violet 421 anti-human CD326 (EpCAM) Antibody (BioLegend, 324220), diluted with staining buffer, was added, and the samples were allowed to stand at 4°C for 50 minutes.After washing the cells once with staining buffer, they were resuspended in staining buffer containing 1 / 200 volume of 7-AAD solution, and the binding of various antibodies to ascites cells was measured by flow cytometry using CytoFLEX S (Beckman Coulter). Data analysis was performed using FlowJo. The 7-AAD-negative cell fraction, an indicator of viable cells, was separated for CD45, an indicator of immune cells, and EpCAM, an indicator of cancer cells. CD45-negative EpCAM-positive cancer cells were separated for Fsc(lin) and Ssc(lin), and the number of viable cancer cells was determined by removing the fragmented fractions. Furthermore, the expression of the activation marker CD25 in CD4 or CD8-positive cells of the CD45-positive fraction was measured, and the MFI of anti-CD25-PE fluorescence intensity was calculated. Figure 10-1 shows the change in the number of viable cancer cells. The vertical axis shows the relative value of the cell number when the number of cancer cells without antibody solution is set to 100%. Figures 10-2 and 10-3 show the changes in CD25 expression levels on CD4-positive T cells and CD8-positive T cells induced by the test antibody. The vertical axis shows the relative MFI values of anti-CD25-PE fluorescence intensity. As a result, as shown in Figure 10-1, the addition of the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody reduced the number of viable cancer cells in the ascites fluid, and as shown in Figures 10-2 and 10-3, activation of CD4-positive T cells and CD8-positive T cells in the ascites fluid was observed. These results suggest that the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody activates CD4-positive T cells and CD8-positive T cells in the ascites fluid, thereby killing cancer cells in the ascites fluid.
[0209] [Example 11: In vivo antitumor evaluation of anti-TSPAN8-anti-CD3 bispecific antibody] The in vivo antitumor activity of an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody was evaluated using a gastric cancer peritoneal dissemination model. [Example 11-1: Production of Expanded panT Cells] Anti-CD3 antibody (BioLegend, 317315) dissolved in PBS at a concentration of 3 μg / mL was added to each 24-well plate (IWAKI, 3820-024) at 250 μL and allowed to stand at 4°C. The following day, the plates were washed twice with culture medium, then culture medium was added, and the plates were left to stand at room temperature until cell seeding as described below. PanT cells (including both CD4T cells and CD8T cells) were isolated from HPBMC, human peripheral blood mononuclear cells, cryopreserved (LONZA, CC-2702). PanT Cell Isolation Kit, human (Miltenyi Biotec, 130-096-535) was used for isolation, and the experiment was performed according to the attached protocol. The culture medium was removed from the aforementioned 24-well plates, and 3 × 10⁶ cells were added to the plates with culture medium. 6 PanT cells, prepared to a concentration of 1 / mL, were seeded in 500 μL portions. Further, 500 μL of culture medium containing 20 ng / mL human IL-2 (PeproTech, 200-2) and 2 μg / mL anti-CD28 antibody (BioLegend, 302923) was added to each portion, and the cells were cultured at 37°C in a 5% CO2 incubator. The cells were subcultured on new plates (IWAKI, 3810-006) at 3, 5, and 7 days after the start of culture, and IL-2 was added to a final concentration of 10 ng / mL. Cells were harvested at 7 and 10 days after the start of culture and used in Example 10-2. The cells isolated and grown here are referred to as Expanded panT cells.
[0210] [Example 11-2: Confirmation of drug efficacy in a gastric cancer peritoneal dissemination model] Seven 7-week-old female C.B17 / Icr-scid / scidJcl mice (Claire Japan Co., Ltd.) were introduced into the peritoneal cavity of each group, with 1 × 10⁶ mice present. 6 60As6-Luc / GFP cells were transplanted at a dose of 1 mL / PBS. Six days after transplantation, the luminescence of the substrate Luciferin, induced by Luciferase introduced into the 60As6-Luc / GFP cells, was used as an indicator, and the cells were divided into groups to ensure equal distribution. Luciferin luminescence was used as an indicator of tumor volume. In detail, each individual receives 3 mg of Luciferin (VivoGlo A 0.5 mL solution of Luciferin (In Vivo Grade, Promega, P1043) dissolved in PBS was administered intraperitoneally, and the luminescence was measured 10 minutes after administration using IVIS Lumina II (Perkinelmer). Next, 1 × 10⁶ cells were measured 7 and 10 days after 60As6-Luc / GFP cell transplantation. 7 Expanded panT cells were suspended in 0.5 mL of PBS, and 0, 0.3, 1.0, and 3.0 mg / kg of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody was administered intraperitoneally in 0.2 mL of PBS. Fourteen days after gastric cancer cell transplantation, the luminescence of Luciferin was measured to evaluate the increase or decrease in tumor volume. The survival of the peritoneal dissemination model mice was also observed until 34 days after 60As6-Luc / GFP cell transplantation. As shown in Figure 11-1, a significant reduction in tumor volume was observed in the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody administration group, and as shown in Figure 11-2, a significant extension of survival time was observed in the 1.0 and 3.0 mg / kg administration groups. Table 4 shows the median survival and test results. The significance probabilities (P-values) in the table were determined by comparing the survival time of the control group (solvent-administered group) with that of the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody-administered group using a log-rank test. ** indicates groups where the P-value is smaller than the significance level of 0.01 / 3 adjusted by Bonferroni's method. [Table 4]
[0211] [Example 12: Effects of anti-TSPAN8-anti-CD3 bispecific antibodies on various cancer cell lines] [Example 12-1: Confirmation of binding activity of anti-TSPAN8 antibody to various cancer cell lines] The binding of Alexa Fluor647-labeled 16B11 to gastric cancer cell lines (KATOIII cells: Japanese Collection of Research Bioresources (JCRB), JCRB0611; NUGC-4 cells: RIKEN BioResource Research Center (BRC), RCB1939; 60As6-Luc / GFP cells), colon cancer cell lines (HT-29 cells: ATCC, HTB-38; LoVo cells: ATCC, CCL-229; GP2d cells: The European Collection of Authenticated Cell Cultures (ECACC), 95090714), pancreatic cancer cell line (AsPC-1 cells: ATCC, CRL-1682), esophageal cancer cell line (OE19 cells: ECACC, 96071721), and liver cancer cell line (Li-7 cells: RIKEN BRC, RCB1941) was measured by flow cytometry. As a negative control antibody, our proprietary anti-KLH antibody (173A1) labeled with Alexa Fluor647 was used. Figure 12 shows histograms of the binding of 16B11 to the negative control antibody in each cancer cell line.
[0212] [Example 12-2: Evaluation of RTCC activity of anti-TSPAN8-anti-CD3 bispecific antibodies against various cancer cell lines] KATOIII cells, NUGC-4 cells, HT-29 cells, LoVo cells, GP2d cells, AsPC-1 cells, OE19 cells, and Li-7 cells were cultured in 2 × 10⁶ cells in culture medium. 5 The culture medium was prepared at 1 × 10⁶ cells / mL, and 50 μL was seeded into each of the 96 flat-bottom plates (IWAKI, 3860-096). The cultures were incubated at 37°C in a 5% CO₂ incubator. 6Frozen human peripheral blood mononuclear cells (LONZA, CC-2702), prepared at a concentration of 100 μL / mL, were seeded into 96-well plates under culture. Anti-TSPAN8(16B11)-anti-CD3 bispecific antibody was diluted in culture medium to a 2:1 ratio, with a maximum concentration of 40 μg / mL or 20 μg / mL. 50 μL of the diluted anti-TSPAN8(16B11)-anti-CD3 bispecific antibody was added (maximum final concentration of 10 μg / mL or 5 μg / mL). The 96-well plates containing the cancer cell line, frozen human peripheral blood mononuclear cells, and antibody were cultured at 37°C in a 5% CO2 incubator. After 3 days, the cells were harvested and seeded into V-bottom microplates. Cells adhering to the culture plate at harvesting were detached with Accutase (Innovative Cell Technologies, AT104) and then added to the V-bottom microplates. After centrifugation at 720×g for 2 minutes, the supernatant was removed, and 20 μL / well of a solution of 1 / 40th the volume of Human BD Fc Block added to the staining buffer was added. To each well, 10 μL / well of APC Mouse Anti-Human CD4 (Becton, Dickinson and Company, 555349), APC-H7 Mouse Anti-Human CD8, Brilliant Violet 421 Mouse Anti-Human CD45 (Becton, Dickinson and Company, 563879), and PE Mouse Anti-Human CD25, diluted in staining buffer, were added, and the mixture was allowed to stand at 4°C for 1 hour. After washing once with staining buffer, 1 / 200th the volume of 7-AAD solution was added. The mixture was resuspended in staining buffer, and the binding of each antibody was measured by flow cytometry using CytoFLEX S. Data analysis was performed using FlowJo. The number of CD45-negative cells in the 7-AAD-negative cell fraction, an indicator of viable cells, was defined as the number of viable cancer cells. The value of cells without antibody solution was set to 100%.Furthermore, for CD4 or CD8-positive cells in the CD45-positive fraction, the expression of the activation marker CD25 was calculated as the multiplier change in anti-CD25-PE fluorescence intensity (MFI), with the value of no antibody solution added set to 1. As a result, as shown in Figure 13-1, the addition of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody reduced the number of viable TSPAN8-expressing cancer cells. In addition, as shown in Figures 13-2 and 13-3, activation of CD4-positive T cells and CD8-positive T cells was observed, respectively.
[0213] [Example 12-3: Efficacy confirmation in a human PBMC-transplanted HT-29 cell subcutaneous tumor model] Normal human PBMCs (Precision for Medicine, 33000-10M) were divided into 1.25 × 10⁻¹⁰ units. 7 The granules were suspended in PBS to a concentration of 10 cells / mL and administered to 6-week-old NOD / Shi-scid, IL-2RγKO (NOG) female mice (in vivo science) in 2.5 × 10⁶ doses. 6 Cells were injected into the tail vein of mice at a dose of 200 μL. Ten days after human PBMC transfer, HT-29 cells were divided into 5 × 10⁶ cells. 7 Suspend in PBS to a concentration of 5 × 10⁻¹⁶ particles / mL. 6 HT-29 cells were subcutaneously implanted in mice at a dose of 100 μL. Ten days after tumor implantation, tumor volume was measured using calipers, and the mice were divided into groups to ensure equal distribution (n=10). Administration of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody was started on the same day. The first day of administration was defined as day 0. On days 0, 4, and 7, mice were intravenously administered PBS or 0.3, 1, 3, and 10 mg / kg of anti-TSPAN8(16B11)-anti-CD3 bispecific antibody. Tumor volume was measured on days 0, 4, 7, and 11 (Figure 14-1). Tumor volume [mm²] 3 ] was calculated using the following formula. (Length of tumor's long axis [mm]) × (Length of tumor's short axis [mm]) 2 ×0.5 As shown in Figure 14-2, the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody significantly suppressed the growth of HT-29 tumors at doses of 0.3, 1, 3, and 10 mg / kg. [Industrial applicability]
[0214] The anti-TSPAN8 antibody and anti-TSPAN8-anti-CD3 bispecific antibody fusions of the present invention are expected to be useful in the treatment of cancer. Furthermore, the polynucleotide, expression vector, transformed host cells, and method for producing the antibody of the present invention are useful for producing the anti-TSPAN8 antibody and its fusions. [Sequence Listing Free Text]
[0215] The numerical headings in the following sequence list <223> This section provides an explanation of "Artificial Sequence". Specifically, SEQ ID NO: 2 shows the amino acid sequence of human TSPAN8-Myc-DDK, and the nucleotide sequence shown in SEQ ID NO: 1 encodes the amino acid sequence of human TSPAN8 shown in SEQ ID NO: 2. SEQ ID NOs: 4, 6, or 10 are the amino acid sequences of the heavy chain of the anti-TSPAN8 antibody, and the nucleotide sequences shown in SEQ ID NOs: 3, 5, or 9 encode the amino acid sequences of the heavy chain of the anti-TSPAN8 antibody shown in SEQ ID NOs: 4, 6, or 10. The sequences in SEQ ID NOs: 8 or 12 are the amino acid sequences of the light chain of the anti-TSPAN8 antibody, and the nucleotide sequences shown in SEQ ID NOs: 7 or 11 encode the amino acid sequences of the light chain of the anti-TSPAN8 antibody shown in SEQ ID NOs: 8 or 12. SEQ ID NO: 14 is the amino acid sequence of a polypeptide in which the anti-CD3-scFv region and the second Fc polypeptide are linked, and the nucleotide sequence shown in SEQ ID NO: 13 encodes the amino acid sequence of a polypeptide in which the anti-CD3-scFv region and the second Fc polypeptide are linked, as shown in SEQ ID NO: 14. Sequence IDs 15-23 are the amino acid sequences of the various linkers described in the detailed description of the invention. Sequence IDs 24-37 are the amino acid sequences of the CDR and variable region of 16B11 and 16B12. Sequence IDs 38-40 are the amino acid sequences of the signal sequence. Sequence IDs 41-43 are the amino acid sequences of the region with amino acid numbers 126-155 of TSPAN8 in mouse, rat, or cynomolgus monkey, respectively.
Claims
1. An anti-TSPAN8 antibody or an antigen-binding fragment thereof selected from the following (a) and (b): (a) an anti-TSPAN8 antibody or an antigen-binding fragment thereof comprising: a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 66 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of amino acid numbers 99 to 110 of SEQ ID NO: 4; and a light chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 34 of SEQ ID NO: 8, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 56 of SEQ ID NO: 8, and CDR3 consisting of the amino acid sequence of amino acid numbers 89 to 96 of SEQ ID NO: 8; (b) an anti-TSPAN8 antibody or an antigen-binding fragment thereof comprising: a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 10, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 66 of SEQ ID NO: 10, and CDR3 consisting of the amino acid sequence of amino acid numbers 99 to 110 of SEQ ID NO: 10; and a light chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 34 of SEQ ID NO: 12, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 56 of SEQ ID NO: 12, and CDR3 consisting of the amino acid sequence of amino acid numbers 89 to 96 of SEQ ID NO:
12.
2. The anti-TSPAN8 antibody or antigen-binding fragment thereof of claim 1, selected from the following (a) and (b): (a) an anti-TSPAN8 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 121 of SEQ ID NO: 4 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 107 of SEQ ID NO: 8; (b) An anti-TSPAN8 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 121 of SEQ ID NO: 10, and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 107 of SEQ ID NO:
12.
3. The anti-TSPAN8 antibody of claim 2, selected from the following (a) and (b): (a) an anti-TSPAN8 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 4 and a light chain consisting of the amino acid sequence of SEQ ID NO: 8; (b) An anti-TSPAN8 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 10 and a light chain consisting of the amino acid sequence of SEQ ID NO:
12.
4. An anti-TSPAN8 antibody or antigen-binding fragment thereof described in any one of claims 1 to 3, which is post-translationally modified.
5. An anti-TSPAN8 antibody or its antigen-binding fragment described in claim 4, wherein the post-translational modification is pyroglutamylation of the N-terminus of the heavy chain variable region and / or deletion of lysine at the C-terminus of the heavy chain.
6. A fusion or complex of an anti-TSPAN8 antibody or its antigen-binding fragment described in any one of claims 1 to 5, or a cell expressing an anti-TSPAN8 antibody or its antigen-binding fragment described in any one of claims 1 to 5 on the cell surface.
7. A host cell selected from the following (a) or (b): (a) a host cell comprising a polynucleotide comprising a base sequence encoding a heavy chain variable region of the anti-TSPAN8 antibody of claim 1 and a polynucleotide comprising a base sequence encoding a light chain variable region of the anti-TSPAN8 antibody of claim 2; (b) a host cell comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-TSPAN8 antibody described in claim 2 and a polynucleotide comprising a base sequence encoding the light chain of the anti-TSPAN8 antibody described in claim 3.
8. A method for producing an anti-TSPAN8 antibody or an antigen-binding fragment thereof, comprising a step of culturing a host cell described in claim 7.
9. An anti-TSPAN8 antibody or antigen-binding fragment thereof described in any one of claims 1 to 5, or a fusion, complex or cell described in claim 6, for use in the treatment of cancer.
10. A pharmaceutical composition comprising an anti-TSPAN8 antibody or antigen-binding fragment thereof described in any one of claims 1 to 5, or a fusion, complex, or cell described in claim 6, and further comprising a pharma- ceutically acceptable excipient.
11. The pharmaceutical composition of claim 10 for the treatment of cancer.
12. Use of an anti-TSPAN8 antibody or antigen-binding fragment thereof described in any one of claims 1 to 5, or use of a fusion, complex or cell described in claim 6 in the manufacture of a pharmaceutical composition for the treatment of cancer.
